FORM 2 THE PATENTS.ACT, 1970 (39 of 1970) & THE PATENTS RULES, 2003 COMPLETE SPECIFICATION (See section 10, rule 13) "ANALGESIC COMPOUNDS, METHODS, AND FORMULATIONS" ELI LILLY AND COMPANY, a corporation of the State of Indiana, United States of America, having a principal place of business at Lilly Corporate Center, City of Indianapolis, State of Indiana 46285, United States of America. The following specification particularly describes the invention and the mariner in which it is to be performed. ANALGESIC COMPOUNDS, METHODS, AND FORMULATIONS Opiates, a class of centrally acting compounds, are the most frequently used agents for pain control and alleviation, and which act upon one or more of the human or mammal opiate receptors. Technically, opiates are the natural alkaloids found in the resin of the opium poppy, but current usage of the term includes synthetic variations, termed opioids. Opiates are narcotic agonistic analgesics and are drugs including or derived from opium, such as morphine, codeine, and many synthetic Congeners of morphine, with morphine and hydrocodone preparations being the most widely used opiates. Opiates are natural and synthetic drugs with morphine-like actions, and are subject to control under U.S. Federal narcotics law (scheduled drugs) and the laws of most other nations and international organizations because of their addicting properties and the subsequent destructive toll exacted on the abusers and those with any connection to them. Tramadol is a sunthetic analog of the phenanthrene alkaloid codeine and, as such is an opioid and also a prodrug (codeine is metabolized to morphine, tramadol is converted to M-1 also called O-desmethyltramadoi). Tramadol, like the opiates, is associated with adverse effects, such as physical and psychological dependence, severe withdrawal symptoms, as well as other somewhat less serious side-effects, including nausea, vomiting, sweating, constipation, and drowsiness. While the opiates and related~drugs clearly serve useful purposes, alternative therapies and compounds for alleviation of pain are desirable due to the known problems of the opiates. Particularly, compounds which are not scheduled, allow for lower dosing frequency, and/or do not exhibit the side-effects either at all or to the degree associated with the opiates and related drugs, would provide such alternative therapies. Provided are analgesic compounds, and salts thereof, of formula I: I wherein A is R1 is hydrogen, C1-C5 alkyl, C1-C5 alkoxy, C1-C5 haloalkyl, C1-C5 alkanol, C1-C5 alkyl)phenyl, or phenyl, or a group of the formula -C(0)-R12, where R12 may be C1-C5 alkyl, C1-C5 alkoxy, C1-C5 haloalkyl, C1-C5 atkanol, -C1-C5 alkyl)phenyl, or phenyl; R2 is hydrogen, C1-C5 alkyl, C1-C5 alkoxy, halogen, C1-C5 haloalkyl, or C1-C5 haloalkoxy; R3 is hydrogen, C1-C5 alkyl, C1-C5 alkoxy, halogen, C1-C5 haloalkyl, or C1-C5 haloalkoxy; R* is hydrogen, C1-C5 alkyl, or -(C1--C5 alkyl)phenyl; R5 is hydrogen, C1-C5alky^ or-(C1-C5 alkyl)phenyl; R6 is hydrogen, hydroxy* or is absent; R7 is hydrogen; R8 is hydrogen or methyl; R9 is hydrogen or methyl; R10 is hydrogen; Ru is hydrogen or C1-C5 alkyl; or R7 and R10 combine to form-CH2-or-{CH2)2S or R8 and R9 combine to form a cyclopropyl group with the carbon to which they are attached; or R10 and R1! combine to form-CH2-or-(CH2)3-■ More particularly, A may be: Of the first four definitions immediately above for A, the following are preferred: C1-C5 alkyl refers to straight chain and branched alkyls having one to five carbon atoms, and includes methyl, ethyl, propyl, n-buryl, iso-butyl, pentyl, isopentyl, and neopentyl. C1-C5 alkoxy refers to straight chain and branched alkoxys having one to five carbon atoms, and includes methoxy, ethoxy, propoxy, n-butoxy, iso-butoxy,pentoxy, isopentoxy, and neopentoxy. Halogen or halo refers to fluorine, bromine, chlorine, and iodine. Haloalkyl as used herein refers to an alkyl (as noted above) substituted with one or more halo atoms. Such groups include trifluoromethyl, methylchloride, dichloromethyl, pentylchloride, butyl chloride, and isopropyl chloride. Haloalkoxy refers to an alkoxy group, as described herein, which is substituted with one to six halo groups. Examples of fluoroalkoxy groups include fluoromethoxy, difluoromethoxy, trifluoromethoxy, pentafluoroethoxy, and trifluoroethoxy. C1-C5 alkanols refer to methanol, ethanol, propanol, or methoxyethanol. In the definition of A: PivCl refers to pivaloyl chloride. Controlling pain refers to either suppressing, inhibiting, ameliorating, reducing, or eliminating pain, its severity, and/or duration. As such, the invention is applicable to the alleviation of existing pain as well as the suppression or inhibition of pain which would otherwise ensue from an imminent pain-causing event. The pain being alleviated can be chronic or acute. Mammal includes both human or non-human mammals. Non-human mammals include domestic animals, such as livestock animals and companion animals. Livestock animals include cattle, camellias, pigs, sheep, goats, and horses. Companion animals include dogs, rabbits, cats, and other pets owned and maintained in close association with humans as part of the human-animal bond. Effective amount refers to the amount of a compound of formula I, or a salt thereof, sufficient to control or alleviate pain in a mammal in need thereof, and as such will depend upon several factors. Ranges for a compound of formula I, or a salt thereof, in the methods include from 0.01 to 1000 mg/kg and more desirably, 0.1 to 100 mg/kg of the animal's body weight, The frequency of the administration will also be dependent upon several factors, and can be a single dose administered once a day or once a week for a duration determined by the attending doctor or veterinarian. The dose can be also be split into two or more smaller doses given in a timeframe to result in the control or alleviation of pain. Pharmaceutically acceptable as used in this application, for example with reference to salts and formulation components such as carriers, includes "veterinarily acceptable", and thus includes both human and animal applications independently. : Pharmaceutically acceptable salts, and common methodology for preparing them, are known in the art. See, e.g., P. Stahl, et al., HANDBOOK OF PHARMACEUTICAL SALTS: PROPERTIES, SELECTION AND USE, (VCHA/Wiley-VCH, 2002); S.M. Berge, et al, Pharmaccutical Salts, Journal of Pharmaceutical Sciences, Vol. 66, No. 1, January 1977. A . preferred salt is the hydrochloride salt. The compounds of formula I and their salts may be formulated as pharmaceutical compositions for systemic administration. Such pharmaceutical compositions and processes for making the same are known in the art for both humans and non-human mammals. See, e.g., REMINOTON: THE SCIENCE AND PRACTICE OF PHARMACY, (A. Gennaro, et al., eds., 19th ed., Mack Publishing Co., 1995). Additional active ingredients may be included in the formulation containing a compound of formula I or a salt thereof. Carrier is used herein to describe any ingredient other than the active components) in a formulation. The choice of carrier will to a large extent depend on factors such as the particular mode of administration, the effect of the carrier on solubility and stability, and the nature of the dosage form. The compounds of the invention may be made by the following described procedures, as well as the procedures described in Selnick, H. C; Bourgeois, M. L.; Butcher, J. W.; Radzilowski, E. M. Tetrahedron Lett, 1993,34,2043; Alvarado, C; Guzman, A.; Diaz, E.; Patino. R. J. Mex. Chem. Soc 2005,49, 324; Evans, G. R.; Paloma, Fernandez, D.; Henshilwood, J. A., Lloyd, S.; Nicklin, C. Org. Process Res. Dev. 2002,6, 729; and Mohacsi, E.; O'Brien, J. P.; Blount, J. F. JMeterocycLCkem. 1990,27,1623. The invention provides a pharmaceutical formulation comprising a compound of formula I, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers. The pharmaceutical formulation may further comprise at least one additional active ingredient. A pharmaceutical formulation may be a human pharmaceutical formulation or a veterinary pharmaceutical formulation. The invention provides a method of controlling pain in a mammal in need thereof comprising administering an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, to said mammal. The method may further provide administering at least one other active ingredient to said mammal. The mammal may be a human or non-human mammal, and further may be a companion animal, such as a dog or cat. For compounds of the formula Ia, below, Schemes A-C and Preparations and/or Examples 1 -76 illustrate methods of preparing them. R Preparation 1 Synthesis of 2-dimemylaminomethyl-bicyclo[3^. 1 ]octan-3-one Stir a mixture of bicyclo[3.2.1]octan-3-one(5.2g,41.9mmoI),(HCHO)n(1.51 g, 50,3 mmol), dimemylamine hydrochloride (3.42 g, 41.9 mmol) and 0.5 mL of conc. HCl in MeCN (50 mL) at 80 °C for 2 hours. After removal of the solvent under vacuum, dissolve the residue in H2O (20 mL) and wash with EtOAc (20 mL x 3). Basify the aqueous solution with NaOH to pH = 10. Extract the resultant aqueous mixture with EtOAc (60 mL x 3); The combined organic layers are washed with brine (10 mL), dried over Na2SO4, filtered, and concentrated under vacuum to give crude 2-dimethylaminomethyl- bicyclo[3.2.1]octah-3-one as brown oil (5.9 g, yield: 78.7%). MS(m/z): 182 (M+l). Example 2 Synthesis of 2-dimethyiaminomethyl-3-(3-metfioxy-phenyl)-bicyclo[3.2.l]octan-3-ol. Add dropwise a solution of f-BuLi (19.2 mL, 25.Q mmol) in hexane via syringe to a solution of l-bromo-3-methoxyrbenzene (3.74 g, 20.0 mmol) in THF (60 mL) at -78 °C under N2. After being stirred at -78 °C for 1 hour, add dropwise a solution of 2-dimethylaminomethyl-bicyclo[3.2.1]octan-3-one(1.81 g, 10.0 mmol) in THF (10 mL) to the reaction mixture and stir the resultant mixture at -78 °C for additional 1 hour. Quench the reaction with saturated aqueous NH4CI solution (20 mL). Extract the aqueous mixture with EtOAc (50 mL x 3). The combined organic layers arc washed with brine (15 mL), dried over Na2SO4, filtered, and concentrated under vacuum Purify the residue by silica ge! chromatography (CH2Cl2:MeOH = 30:1) to afford 2-dimethylaminomethyi-3- (3-methoxy-phenyl)-bicyclo[3.2.1]octan-3-ol as white solid (1.49 g, yield: 51%). MS (m/z): 290 (M+l). The following compounds may be prepared essentially by the Method of Example 2. Ex. No. Chemical name Structure Physical data 3 2-Dimethylaminomethyl-3 -(3-fluoro-5-methoxy-phen yl>bicyclo[3.2.1]octan-3-o I F MS (m/z): 308 (M+l). 4 2-Dimethylaminomethyl-3 -{5-methoxy-2-triflxiorome thoxy-phenyI)-bicyclo[3.2. lJoctan-3-ol MS (m/z): 374 (M+l). 5 .. 2-Dimethylaminomethyl-3 -(2-fIuoro-5-methoxy-phen -yl>bicyclot3.2.1]octan-3-o I r JTOH H ~^H MS (m/z): 308 (M+l). 6 2-Dimethylaminomethyl-3 -(4-fluoro-3-methoxy-phen yl)-bicyclo[3.2.1 ]octan-3~o 1 H*^^Sl MS (m/z): 308 (M+l). 7 2-Dimethylaminomethyl-3 -(2-fluoro-3-methoxy-phen yI>bicycIo[3.2.1 ]octan-3-o 1 -%' MS (m/z): 308 (M+l). 8 2-DimethyIaminomethyU3 -(3-methoxy-5-methyl-phe ny l>bicyclo[3.2.1 ]octan-3-ol MS (m/z): 304 (M+l). Ex. No. Chemical name Structure Physical data 9 3-(2-Chloro-5-methoxy-ph enyl)-2-dimethylamuioniet hyl-bicyclo[3.2. l]octan-3-oi MS (m/z): 324 (M+l). 10 11 3-(3-Chloro-5-methoxy-ph enyl)-2~dimethylaminomet hyl-bicyclo[3.2. l]octan-3-ol MS (m/z): 324 (M+l). 2-Dimemytamraomethyl-3 -(5-methoxy-2-methyl-phe nyl)-bicyclo[3.2.1]octan-3-ol MS (m/z): 304 (M+l). 12 2-Dimcthylarninomethyl-3 -(3-methoxy-4-methyl-phe nyl)-bicyclo[3.2.1]octan-3-ol H*^**H MS (m/z): 304 (M+l). 13 2-Dimemylaminomethyl-3 -(3-hydroxy-phenyl)-bicyc lo[3.2.13octari-3-ol HO i*r^ MS (m/z): 276 (M+l). Example 14 Synmesisof2-dimemyIarru^omethyl-3-(3-memoxy-phenyl)^bicyclo[3.2.1]octan-3-ol hydrochloride. Add H2O (100 mg, 5.56 mmol) and TMSCl (361 mg, 3.34 mmol) to a solution of 2-dimethylaminomethyl-3.(3_methoxy-phenyl)-bicyclo [3.2.1] octan-3-ol (877 mg, 3.03 mmol) in 2-butanone (60 mL). Stir the mixture at ambient temperature for 12 hours. Concentrate the mixture under vacuum to give 2-dimemylaminomethyl-3-(3-methoxy- phenyI)-bicyclo[3.2.1]octan-3-ol hydrochloride as white solid (986 mg, Yield: 100%). *H NMR (400 MHz, D20) 5 7.23-7.27 (t, J= 16.4,1H), 7.00-7.02 (d,j= 8.0,1H), 6.95-6.96 (t, J= 4.0,1H), 6.78-6.80 (d,J= 10.4,1H),3.71 (s, 3H), 3.05-3.19 (m, 1H), 2.52-2.58 (m, 4H), 2.14-2.26 (m, 4H), 2.09-2.14 (m, 2H), 2.05-2.06 (d, J= 2A, 1H), 1.89-1.92 (m, IH), 1.78-1.80 (m, 1H), 1.51-1.68 (m, 4H), 1.40-1.52 (m, 1H). The following compounds may be prepared essentially by the method of Example 14, Ex. No. Chemical name Structure Physical data 15 2-Dimethylaminomet hyl-3-(3-fluoro-5-met hoxy-phenyl)-bicyclo [3.2.1]octan-3-ol hydrochloride lH NMR (400 MHz, Methanol-d4) 5 6.92 (s, IH), 6.88-6.85 (d,J= 12.0,1H), 6.62-6.59 (aV= 12.0,1H), 3.82 (s,3H), 2.80 (s,3H), •2.74-2.70 (d,y= 16.0,- 1H), 2.51-2.48 (m, 4H), 2.40 (s, 1H), 2.30-2.25 (m, 3H), 2.27-2.24 (d, y = 12.0,2H), 2.17-2.15 (m, 1H), 1.81-1.64 (m,4H). 16 2-DmiethyIaminomet hyl-3-(5-methoxy-2-t rifluoromethoxy-phe nyl)-bicyclo[3.2.1 ]oc tan-3-ol hydrochloride 'H NMR (400 MHz,, D20) 8 7.24-7.26 (d,y= 8.4, IH), 7.13 (s, 1H), 6.86-6.88 (d,J= 8.8, 1H), 3.73 (s,3H), 3.11-3.17 (m, ' IH), 2.65(s, 3H), 2.48-2.55 (m, 2H), 2.18-2.39 (m,6H), 1.92-1.94 (m,lH), 1.60-1.75 (m, 5H), 1.48-1.56 (m, IH). 17 2-Dimethylaminomet hyt-3-(2-fluoro-5-met hoxy-phenyl)-bicyclo [3.2.1]octan-3-ol hydrochloride 'H NMR (400 MHz, D20) 5 6.98-6.70 (m,2H), 6.79-6.81 (m, IH), 3.70 (s, 3H), 3.08-3.11 (t,J=12.8, IH), 2.55-2.62 (m, 4H), 2.25-2.48 (m, 6H), 2.17 (s, IH), 1.85-1.94 (m, IH), 1.49-1.57 (m,6H). 18 2-Dimethylaminomet hy[-3-(4-fluoro-3-met hoxy-phenyl)-bicyclo [3.2.1]octan-3-oi hydrochloride 'H NMR (400 MHz, D20) 8 7.12-7.06 (m, 2H), 7.08 (s, 1H), 3.82 (s, 3H), 2.64-2.57 (m, 3H), 2.35 (m, 2H),2.31(s, 1H), 2.21-2.11 (m,2H), 2.12 (s, 6H), 1.87-1.74 (m,2H), 1.66-1.48 (m,3H). 19 2-Dimethylaminomet hyl-3-(2-fluoro-3-met hoxy-phenyl)-bicyclo [3.2.1]octan-3-ol hydrochloride 'H NMR (400 MHz, D20) 8 7.11-7.01 (m, 3H), 3.77 (s, 3H), 3.14-3.09 (m,lH), 2.63-2.57 (m, 4H), 2.45-2.26 (m, 5H), 2.18 (s,lH) 2.06 (s,lH), 1.95-1.90 (m,lH), 1.79-1.74 (m, 1H), 1.69-1.53 (m,4H), 1.51-i;47(tn,lH); : 20 2-Dimethylaminomet hyl-3-(3-methoxy-5-methyl-phenyl)-bicyc lo[3.2.1]octan-3-ol hydrochloride *H NMR (400 MHz, D20) 8 6.86 (s.lH), 6.76 (s, 1H), 6.65 (s, 1H), 3.69 (s, 3H), 3.03-3.09 (m, 1H), 2.60 (s, 3H), 2.52-2.55 (d, J= 13.2,1H), 2.33 (s,3H), 2.14-2.24 (m, 6H), 2.04-2.08 (d, J= 14.4,1H), 1.90- 1.94 (m, 1H), 1.76-1.80 (m,lH), 1.58-1.66 (m,4H), 1.45-1.49 (m, 1H). 21 3-(2-Chloro-5-metho xy-pienyl>2-dimetfa ylaminomethyl-bicyc lo[3.2.1]octan-3-ol hydrochloride !HNMR(400MHz, ■Methanol-d4) 5 7.44-7.45 (d, J = 3.2,1H), 7.32-7.34 (&,J= 8.8,1H), 6.86-6.89 (m, 1H), 3.73 (s, 3H), 3.27-3.30 (t, 7= 13.6,1H), 3.05-3.07 (d, J = 9.2, 1H), 2.90-2.94 (m, 1H), 2.81 (s, 3H), 2.71-2.75 (d, .7=13.6, ' 1H), 2.47 (m, 5H), 2.29-2.35 . (m,lH), 2.03-2.12 (m,2H), 1.59-1.79 (m,4H). 22 3-(3-Chlqrb-5-metho xy-phenyl)-2-dimeth ylaminomethyl-bicyc lo[3.2.1joctan-3-ol hydrochloride 1HNMR(400MHz, Methanol-d4) 8 7.12 (s, 1H), 7.02 (t, J- 2.0,1H), 6.85-6.86 (1,7=4.0,1H), 3.82 (s,3H), 3.36 (m,lH), 2.68-2.71 (m, 7H), 2.36-2.37 (m, 2H), 2.25-2.28 (m, 2H), 2.14-2.18 (m, 1H), 2.03-2.09 (t, >= 23.6, 1H), 1.70-1.86 (m,4H), 1.59-1.67 (m, 1H). 23 2-Dtmethylaminomet hyl-3-(5-methoxy-2- methyl-phenyl)-bicyc io[3.2.1]octan-3-ol hydrochloride * 'HNMR (400MHz, D20) 5 7.26 (s, 1H), 7.21-7.19 (d,7-8.0,1H), 6.88-6.86 (d, J= 8.0, 1H), 3.81 (s, 3H), 3.23-3.17 (m, 1H), 3.71-3.66 (m,3H), 2.59-2.51 (m,6H), 2.41 (s,4H), 2.32 (s,lH), 2.04-2.01 (mJH), 1.90-1.88-(m,2H),1.75-l%67 (m,2H), 1.63-1.59 (m, 2H). 24 2-Dimethylaminomet hyl-3-(3-methoxy-4^ methyl-pheiiyl)~bicyc Io[3.2.1]octan-3-ol hydrochloride jT'jl OH OH 'HNMR(400MHz,D2O)5 7.23-7.21 (d,*/ = 4.0,1H),7.05 (s, 1H), 7.03 (s,lH), 3.85(s, 3H), 3.22-3.18 (m,lH), 2.71-2.64 (m,4H), 2.42 (s, 3H), 2.36-2.27 (m, 3H), 2.20-2.16 (m, 4H), 2.08-2,02 (m, 1H), 1.94-1.90 (m,lH), 1.88-1.75 (m,4H), 1.60-1.56 (m, IH). *H NMR (400 MHz, D20) 5 7.14-7.18 (t,J= 15.6; IH), 6.91-6.93 (d,y= 7.2,1H),6.85 (s, IH), 6.64-6.66 (d, J= 6.8, 2-Dimethylaminomet 1H), 3.00-3.06 (t, .7=22.8,IH), hyl-3-(3-hydroxy-phe 2.53-2.57 (m, 4H), 2.28 (s, 3H), 25 nyl)-bicyclo[3.2.1]oc 2.22 (s, 1H), 2.12-2.14 (m, 2H), • tan-3-ot hydrochlorid 2.01-2.(T5(d, .7=13.6,IH), e 1.90 (m,lH), 1.76 (m, IH), 1.60-1.65 (m,4H), 1.45 (m, 1H). Add TBSC1 (3.37 g, 22.37 mmol) and imidazole (1.9 g, 27.96 mmol) to a solution of 3-bromo-4-fluoro-phenol (3.56 g 18.64 mmol) in CH2C12 (60 ml). Stir the solution at ambient temperature for 3 hours. Quench the reaction with water (30 mL). Extract the aqueous layer with CH2C12 (30 mL x 3). The combined organic layers are washed with brine, dried over Na2SO4, concentrated under vacuum. The residue is purified by silica gel chromatography (petroleum ether) to give (3-bromo-4-fluoro-phenoxy)-tert-butyl- dimethyl-silane as colorless oil (5.81 g, 99%), MS (m/z): 303 (M-l). * The following compounds may be prepared essentially by the method of Preparation 26. Prep No. Chemical name Structure Physical data 27 (3-Bromo-5 -fluoro-phenoxy )-tert-butyl-dimethyl-silane MS (m/z): 303 (M-l),. 28 (3-Bromo-5 -trifluororhethyl -j)henoxy)-tert-butyl-dirneth yl-silane MS (m/z): 353 (M-l). 29 (3-Bromo-4-trifluorometho xy-phenoxy)-tert-butyl-dim ethyl-silane MS (m/z): 369 (M-l). 30 (5-Bromo-2-trifluoromethyl -phenoxy)-tert-butyl-dimeth yl-silane MS (m/z): 353 (M-l). 31 (5-Bromo-2-fluoro-phenoxy )-tert-butyl-dimethyl-siiane MS (m/z): 303 (M-l). Prep No. Chemical name Structure Physical data 32. (3-Bromo-2-fluoro-phenoxy )-tert-butyl-dimethyl-silane F MS(m/z):303(M-i). 33 (3-Bromo-5-methyl-phenox y)-tert-butyl-dimethyl-silan e MS (m/z): 299 (M-l). 34 (3-Bromo-4-chloro-phenox y)-tert-butyl-dimethyl-silan e MS(m/z);319(M-l). 35 (3-Bromo-5-chloro-phenox y)-tert-butyl-dimethyl-silan e a MS (m/z): 319 (M-l). .36 (3-Brorno-4-methyl-phenox y)-tert-butyl-dimethyl-silan e MS (m/z): 299 (M-l). 37 (5-Bromo-2-methyl-phenox y)-tert-butyl-dimethyl-silan e TBSO^^^^Br MS(m/z):299(M-l). 38 (5-Bromo-2,3-difluoro-phen oxy)-tert-butyl-dimethyl-sil ane TBSO'^Sr MS (m/z): 321 (M-l). Example 39 Synthesis of 2-dimemylammomethyl-3-(2-fluoro-5-hydroxy-phenyl)-bicyclo[3.2.1 ]octan -3-ol Cool a solution of (3-bromo-4-fluoro- pheiioxy)-tert-butyl-dimethyl-silane (5.81 g, 19.03 mmol) in THF (100 mL) to -78 °C under N2. Then add dropwise a solution of f-BuLi (14.6 mL, 19.03 mmol) in hexane via syringe-to the reaction solution. After being stirred at -78 °C for 1 hour, add dropwise a solution of 2-dimethylaminomethyl-bicyclo [3.2.1]octan-3-one (2.87 g, 15.86 mmol) in THF (1.5 mL) to the reaction mixture and stir the mixture at -78 °C for additional 1 hour. Quench the reaction with 60 mL of diluted HC1 (2N), and stir at ambient temperature for 2 hours. Basify the resultant mixture with K2CO3 to pH - 9, and extract with EtOAc (100 mL X 3). The combined organic layers are washed with brine, dried over Na2SO4, filtered, and concentrated under vacuum. Purify the residue by silica gel chromatography (CH2CI2 to CH2Cl2:MeOH =10:1) to afford 2-dimethylanunomethyl-3-(2-fluoro-5- hydroxy-pheny!)-bicyclo[3.2.1]octan-3~ol as white solid(2.38g,"yieid:5l.2%).MS(Wz):294(M+l),. The following compounds may be prepared essentially by the method of Example 39. ExT No. Chemical name Structure Physical data 40 2-Dimemylaminomethyl-3-( 3 -fluoro-5-hydroxy-pheny 1) -bicyclo[3.2.1 ]octan-3-ol F MS(m/z):294(M+l). 41- 2-Dimethylaminomethyl-3-( 3-hydroxy-5-trifluoromethy l-phenyl)-bicyclo[3.2.1]octa n-3-ol MS(m/z):344(M+l). Ex. No. Chemical name Structure Physical data 42 2-Dimethylaminomethyl-3-( 5 -hydroxy-2-trifluorometho xy-pheny0-bicyclo[3.2.1]oc tan-3-ol MS (m/z): 360 (M+l). 43 2-DimethyIaminomethyl-3-( 3-hy phenyl ester MS (m/z): 360 (M+l). 68 Benzoic acid 3-(2-di methylarninomethyl-3-hydroxy-bicyclo[3. 2.1]oct-3-yl)-phenyl ester MS(m/z):380(M+l). Ex. No. Chemical name Structure Physical data 69 2,2-Dimethyl-propio nic acid 3-(2-dimethylamino methy 1-3 -hydroxy-M cyclo[3.2.1]oct-3-yl)-5-fluoro-phenyl ester F MS (m/z): 378 (M+l). 70 Benzoic acid 3-(2-di methylaminomethyl-3-hydroxy-bicycIo[3, 2.1]oct-3-yl)-5-fluor o-phenyl ester * MS(m/z):398(M+l), lHNMR(400MHz, Methanol-d4) 5 8.07-8^09 (m, 2H), 7.59-7.61 (t, .7=7.6,1H), 7,45-7.49 (t,J= 15.6,2H), 7.10-7.15 (nv2H), 6.81-683 (d, J-8.8,1H),2.71-2.77 (in, lH),2.27-2J28(m,2H), 2.07-2.13 (m, 7H), 2.04-2.07 (m, 2H), 1.94-2.03 (m, 2H), 1.59-1.74 (m, 4H), 1.45-1.48 (m,lH). Example 71 Synthesis of 2,2-dimethyl-propionic acid 3-(2-dimethylaminomethyl-3-hydroxy-bicycle [3.2.1]oct-3-yl)-4-fluoro-phenyl ester hydrochloride Add H20 (9 mg, 0.5mmol) and TMSC1 (43 mg, 0.397 mmol) to a solution of 2,2-dimethyl-propionic acid 3-(2-dimethylaminomethyl-3-hydroxy-bicycle[3.2.1 ]oct-3- yl)-4-fluoro- phenyl ester (150 mg, 0.397 mmol) in 2-butanone (50 mL). Stir the reaction mixture' at 0 °C for 2 hours. Evaporate the mixture under vacuum to give 2,2-dimethyl- propionic acid 3»(2-dimethylaminomethyl- 3-hydroxy-bicycle [3.2.1]oct-3-yl)-4-fluoro- phenyl ester . hydrochloride as white solid (164mg, Yield: 100%). lH NMR (400 MHz, Methanol-d4) 5 7.30-7.32 (d,J, = 6.8, J3= 2.8,1H), 7.15-7.20 (d, J}= 11.6, J2= 8.8,1H), 7.03-7.06 (m, 1H), 10 3.28-3.31 (m, 1H),2.77-2.81 (m,4H), 2.37-2.52 (m,7H), 2.27 (m, lH),2.03(m, 1H), 1.79-1.86(m, 4H), 1.63-1.65 (m,lH), 1.38 (s,9H). ' Tne following compounds may be prepared essentially by the method of Example 71. Ex. No. Chemical name Structure Physical data 72 Benzoic acid 3-(2-dimethyI aminomethyl-3-hydroxy-bic ydo[3.2. l]6ct-3-yl)4-fluor o-phenyl ester hydrochlori de - 'HNMR^OOMHz, Methanol-d4) 8 8.19-8.21 (m,2H), 7.72-7.76 (t, 7=14.8, 1H), 7.58-7.62 (t,./= 15.6,2H), 7.49-7.51 (t,y=8.0,lH), 7.22-7.24 (m,2H), 2.42-2.87 (m,12H), 2.25-2.28 (m,lH), 2.01-2.03 (m, 1H), 1.79-1.85(111,411), 1.64-1.67 (m, 1H). 73 2,2-Dimethyl-propionic aci d 3-(2-dimethylaminometh yI-3-hydroxy-bicyclo[3.2.1] oct-3-yl)~phenyl esterhydro chloride lHNMR(400MHz, Methanol-d4) 8 7.43-7.44 (d,y= 4.4, 2H),7.24(s, 1H), 6.94-6.95 (m,lH), 3.21-3.22 (m,lH), 2.37-2.81 (m,9H), 2.21-2.30 (m,3H), 2.09-2.11 (m,lH), 1.75-1.88 (m,4H), 1.63-1.65 (m,lH), 1.38 (s,9H). Ex. No. Chemical name Structure Physical data 'HNMR(400MHz, Methanol-d4) 5 8.20-8.22 (t,./= 8.4, 2H), 7.72-7.74 (m, 1H), 7.58-7.62 (t,/= 74 Benzoic acid 3-(2-dttnethyl 15.2,2H), 7.50-7.51 • amioomethyl-3-hydroxy-bic (d,> 5.2, 2H), 7.43 yclo[3.2.1 ]oct-3-yl)-phenyl (s,lH),7.14(m, 1H), ester hydrochloride 3.33 (m, 1H), 2.74-2.86 (m,4H), 2.43-2.48 (m, 4H), 2.24-2.42 (m,4H), 2.01-2.10 (m, 1H), — 1.76-1.92 (m,4H), 1.65-1.66 (m, 1H). Ex. Chemical name Structure Physical data No. .. - "IHNMR(400MHz, ]VIethanol-d4) 6 7.22-7.25 (m, 1H), 75 , 2,2-DimethyI-propiqnic aci ?.07(s, 1H), d 3-(2-dimethylaminometh £.78-6.80(m,lH), yl-3-hydroxy-bidyclo[3.2.1] 125-3.28 (m,lH), ' oct-3-yl)-5-fhioro-pheiiyl e £.72-2.78 (m,4H), ster hydrochloride 2.48(s,3H), H*^' £.38-2.39 (d, .7=4.0, ;2H), 2.17-2.37 (m, 3H),2.03(m,TH), 1.71-1.87 (m,4H), ; 1.64-1.67 (m,lH)i 1.38 (s,9H): Ex. No. Chemical name Structure Physical data 1HNMR(400MHz, Methanol-d4) 8 g.I9-8.21(t,y=8.4, 2H), 7.72-7.74 (t,J = 8.4, 1H), 7.58-7.62 (t, * • J=15.6,2H), 76 7.30-7.33 (d,Ji = Benzoic acid 3-(2-dimethyl 10.4,72=1.6,111), aminomethyl-3 -hydroxy-bic 7.27 (s,lH), yclo[3.2.1]oct-3-yl)-5-fluor 6.98-7.00 (d,yi = 8.8, o-pkeayl cstct hydrochloxi J2 = 2.0,1H), de 2.55-2.81 (m, 8H), 2.41 (m,lH), 2.36 (m, lH),Z21-2.35(m, 3H), 2.08-2.10 (m, 1H), 1.74-1.91 (m, 4H), 1.63-1.67 (m, 1H). For compounds of the formula lb, below, Schemes D and E and Examples 77- 113 illustrate methods of preparing them. Example 77 Synthesis of 3-(4-dmiemylaminomethyl-bicyclo[3.2.13oct-2-en-3-yl)-phenol Add TsOH (5.0 g, 29.1 mmol) to a solution of 2-dimethylaminomethyl-3-(3-hydroxy-phenyl)-bicyclo[3.2.1]octan-3-ol (4.8 g, 17.5 mmol) in toluene (150 mL). Heat the reaction mixture to reflux for 2 hours and then quench the reaction by addition of saturated aqueous K2CO3 (20 mL). Extract the aqueous layer with EtOAc (60 mL x 3). The combined organic layers are washed with brine, dried over Na2SO4 and evaporated under vacuum. Purify the residue by preparative HPLC to yield 3-(4-dimethyl anrmometliyl-bicyclo[3.2.1]oct-2-en-3-yl)-phenol as white solid (2.27 g, 50.2 %). MS (m/z): 258 (M+l). The following compounds may be prepared essentially by the method of Example 77. Ex. No. Chemical name Structure Physical data 78 [3-(3-Methoxy-phenyl)-bicycl o[3.2.1 ]oct-3-en-2-ylmethyi]-a^memyl-amine — MS (m/z): 272 (M+l). 79 [3-(5-Methoxy-2-trifluoromet hoxy-phenyl)-bicyclo[3.2.1]oc t-3-en^2-yImethyl]-dimethyl-a mine MS (m/z): 356 (M+l). 80 3-(4-Dimemylaniinomethyl-bi cyclo[3.2.1 ]oct-2-en-3-yl)-4-tr ifluoromethoxy-phenol MS (m/z): 342 (M+l). 81 [3 -(3-Fluoro-5-methoxy-phen yl>bicyclo[3.2. l]oct-3-en-2~yl methyl]Hiimethyl-amine MS (m/z): 290 (M+l). Ex. .No. Chemical name Structure Physical data 82 3-(4-Dimethylaminomethyl-bi cyclo[3,2.1]oct-2-en-3-yl}-5-fl uoro-phenol MS (m/z): 276 (M+l). 83 [3-(2-FIuoro-5-methoxy-phen yl)-bicyclo[3.2.1 ]oct-3-en-2-yl methyl]-dimeiEhyI-amiiie MS (m/z): 290 (M+l). , 84 3 -(4-Dimethy laminomethyl-bi cydof3.2. l]oct-2-ea-3-yi)~4-fl uoro-phenol MS (m/z): 276 (M+l). 85 [3-(3-Methoxy-5-niethyl-phen yi)-bicyclo[3.2.1]oct-3-en-2-yl methyl]-dimetiiyl-amtne MS (m/z): 286 (M+l). 86 3-(4-DimethyIaminomethyl-bi cyclo[3.2.1]oct-2-en-3-yl>5- methyl-phenol MS (m/z): 272 (M+l). 87 3 -Chloro-5-(4-icycIo[3.2.1fa Add H20 (392 mg, 21.8 mmol) and TMSC1 (1.4 g, 12.9 rnmol) to a solution of 3-(4^imemylaniinomethyl-bicyclo[3.2.1]oct-2-en-3-yl)-phenol (2.8 g, 10.9 mmol) in 2-butanone (200 mL). Stir the reaction mixture at ambient temperature for 12 hours. Collect the precipitate by filter, and wash with EtOAc (30 mL x 2), dry under vacuum to give 3-(4-dimethylaminomethyl-bicyclo[3.2.1]oct-2-en-3-yl)-phenoi hydrochloride as white solid (2.41 g,Yield:75.5%). lBNMR(400MHz,D20) 57.20-7.24 (t,J= 15.6,1H), 6.76-6.81 (m,2H), . 6.72 (s, lH),6.15(d,J=6.4,1H),3.58-3.61 (d, J=12.8, lH),3.08-3.14(t,J=26.0,1H), 2.89-2.92 (m, 1H), 2.88 (s, 3H), 2.76 (s, 3H), 2.56 (m, 1H), 2.45 (m, 1H), 1.72-1.83 (m, 6H). The following compounds may be prepared essentially by the method of Example 91. Ex. No. Chemical name Structure Physical data 92 [3-(3-Methoxy-phenyl)-bicyclo[ 3.2.1]oct-3-en-2 -ylmethyl]-dime thyl-amine hydr; ochloride lH NMR (400 MHz, D20) 8 7.24-7.28 (t,J= 16.0, 1H), 6.82-6.87 (t,J= 20.4, 2H), 6.78 (s,lH), 6.12-6.14 (d,J= 7.2,1H), 3.77 (s, 3H), 3.56-3.59 (m,lH), 3.04-3.11 (m,lH), 2.77-2.86 (m, 6H), 2.54 (m, 1H), 2.42 (m,lH), 2.15 (s, 2H), 1.77-1.80 (m,lH), 1.65-1.75 (m,4H). 93 [3-(5-Methoxy- 2-trifluorometho xy-phenyl)-bicy clof3.2.1]oct-3-e n-2-ylmethyl]-di methyl-amine hydrochloride *H NMR (400 MHz, D2O) 5 7.15-7.18 (d,J= 9.6,1H), 6.81-6.84 (m, 1H), 6.69-6.70 (d,y= 5.6,1H), 6.03-6.01 (d, J= 4.0,1H), 3.68 (s,3H), 3.46-3.47 (d, J = 4.0,1H), 3.01-3.06 (m, 1H), 2.64-2.70 (d, .7=9.6, 6H), 2.32-2.46 (m,4H), 1.16-1.80 (m,6H). Ex. No. . Chemical name Structure Physical data 94 3-(4-Dimethyla minqmethyl-bic yclo[3.2.1]oct-2 -en-3-yl)-4-trtflu oromethoxy-phe nol hydro chlori de 'H NMR (400 MHz, DzO) 8 7.02-7.04 (d,J= 8.8,1H), 6.68-6.71 (d,J= 11.6,1H), 6.56(d,J-3.2,lH), 5.92-5.93 (d,J= 6.8,1H), 3.32-3.37 (d,J= 18.8,1H), 2-.58-2.59 (m, 2H), 2.37-2.54 (m,lH), 2.18 (s, 6H), 1.71-1.88 (m,7H). 95 :" [3-(3-FIuoro-5-metnoxy-phenyl )-bicyclo[3.2.1] oct-3-en-2-yIme thyl]-dimethyl-a mine hydrochlo ride 'H NMR (400 MHz, D20) 5 6.35-6.38 (m,3H), 6.01-6.12 (d, J-6.4,1H), 3.69-3:70 ($>=12, 3H), 3.48-3.50 (m,lH), 3.02-3.09 (m, 1H), 2.68-2.82 (m,7H), 2.49 (s, 1H), 2.36(8,1H), 1.63-1.74 (m,6H). Chemical name Structure Physical data 3-(4-Dimethyla minomethyl-bic yclo[-3.2A)oct-2 -en-3-yl)-5-fluor o-phenol hydroc hloride 'HNMR^OOMHz, Methanol-d4) S 6.44-6.49 (m,2H), 6.41-6.42(d, J= 2.0,1H), 6.18-6.19 (d,J= 6.8,1H), 3.60-3.63 (d,./= •14.0, IH)> 3.16-3.22 (t, J = 25.6,1H), 2.99-3.00 (d, J = 3.6,1H), 2.90-2.93 (d,J= 14.8,6H), 2.64 (s,lH), 2.57(s,lH),1.92-1.954d,J = 10.8,1H), 1.85 (m,5H). [3-(2-Fluoro-5-methoxy-phenyl j-bi'cyclo[3.2J] oct-3-en-2-ylme thyl]-dimethyl-a mine hydrochlo ride lHNMR(400MHz,D2O) 5 6.91-6.96 (m, 1H), ' 6.77-6.79 (m, 1H), 6.66-6,68 (m,W, 6.07-6.08 (d, J=4.0,1H), 3.66-3.67 (d, J = 4.0,3H), 3.47(s,lH),3.03(m,IH), 2.60-2.69 (m,6H), 2.48 (s, 1H), 2.33 (s,lH), 1.62-1.78 (m,7H). Ex. No. Chemical nariie Structure Physical date 98 3-(4-Dimethyla minomethyl-t>ic yclo[3.2.1]oci-2 -en-3-yl)-4-flUOr o-phenol hydroc hloride lH NMR (400 MHz^ DtQ) 8 6.83-6.88 (m, 1H), 6.63-6.67 (in, 1H), 6,54-6.57 (m, 1H), 6.03-6.05 (d, J= 8.0,1H), 3.44-3.48 (d,J= 16.0,1H),-3.01-3.09 (m,lH), 2.61-2.69 (m,7H), 2.48 (s, 110,2.32(8,111), 1.76-1.79 (d,7= 12.0,1H), 1.70-1.71 (d,7=4.0,lH), 1.61-1.65 (m,4H). 99 [3-(3-Methoxy-5-methyl-phenyl )-bicyclo[3.2.1] oct-3-en-2-yline thyi]-dimethyl-a mine hydrochlo ride 'H NMR (400 MHz, Methanol-d4) 8 6.67-6.69 (m,2H),6:57(s,lH), 6.13-6.14 (d,V= 6.8,1H), 3.80 (s,3H), 3.64-3.67 (d, J = 12.4,1H), 3.14-3.26 (m, 1H), 2.86-2.95 (m, 7H), 2.57-2.63 (m,2H), 2.33 (s, 3H), 1.94-1.97 (m,lH), 1.79-1.92 (m,5H). Ex. No. Chemical name Structure Physical data 100 3-(4-DimethyIa minomethyl -bic ydo[3.2.1]oct-2 -en-3-yl)-5-meth yl-phenol hydro chloride 'HNMRC^OMH^DaO) 86.63-6.53 (d,y=U,2H), 6.44 (s,lH), 6.11-6.13 {d,J -6.4,1H), 3,59-3.63 (m, 1H), 3.13-3.19 (m,lH), 2.99-3.00 (mJH), • 2.89-2.97 (m, 6H), 2.55-2.62 (m,2H),Zl8 (s, 3H), 1.80-1.95 (m, 6H). 101 3-Chloro-5-(4-di methylaminome thyl-bicyclo[3.2. lJoct-2-en-3-yl) -phenol hydroch loride ^NMR (400MHz, Methanol~d4) 5 6.71-6.73 (in, 2H), 6.58-6.59 (t,J= 3.6.1H), 6.16-6.18 (d,J= 6.4,1H), 3.62-3.68 (m, 1H), 3.16-3.23 (t,J= 26.0, 1H), 2.90-2.96 (m,7H), 2.56-2.64 (m, 2H), 1.83-1.95 (m,6H). Ex. Chemical name Structure Physical data No. 1HNMR(400MHz,D2O) 87.10(d,y=6.4,lH),6.75 [3-(5-Methoxy- (d,Jj= 2A,J2 = 6.4,1H), 102 2-methyl-phenyl 6.58 (m, 1H), 5.78 (s, 1H), )-bicycio[3.2.1] 3.71 (s,3H), 3.35 (d,y= act-VfcTt-2-vVrfte U.G,lH\,3A2(t,J=l2A,' thyl]-dimethyl-a 1H), 2.62 (s,6H), 2.48 (s, mine hydrochlo 2H), 2.35 (m,lH), 2.06 (s, ride 3H), 1.84 (m,lH), 1.73(m, OH), 1.65 (m,4H). 1HNMR(40GMHz,D2O) 57.21-7.23 (d,J=4.0,lH), 3-(4-Dimethyla 6.82-6.84 (d,y=4.0,1H), * 103 minomethyl-bic 6.69 (s,lH), 6.96-6.97 5 -fluoro-ph enyl ester MS (m/z): 346 (M+l). !H NMR (400 MHz, MethanoI-d4)5 6.86-6.89 (m, 1H), 6.76-6.79 (m, 2H), 6.14-6.15 (d, / = 6.8, 1H), 3.36-3.39 (m, 1H), 2.82-2.85 (m, 1H), 2.54-2.63 (m, 3H), 2.37 (s, 6H), 2.25-2.29 (m, 1H), 1.74-1.87 (m, 6H), 1.31-1.32 (d, J= 6.8, 6H). Ex. No. Chemical name Structure Physical data 109 2,2-Dimet hyl-propio ni acid 3-( 4-dimethyl aminomet hyl-bicycl o[3.2.1]oct -2-en-3-yl) -4-fluoro-phenyl est er MS (m/z): 360 (M+l), 1H NMR (Methanol-d4,400 MHz) 5 7.10 (t, J= 9.6, 1H), 6.97 (m, IH), 6.88 (m, 1H), 6.12 (d, J= 9.6, 1H), 3.48 (m, 1H), 2.85 (t, J= 12.4, 1H), 2.61 (s, 2H), 2.52 (s, 6H), 2.33 (m, 1H), 1.94 (m, 1H), 1.83(m, 5H), 1.38 (s,9H). 110 Ispbutyric acid 3-(4 -diinethyla minometh yl-bicyclo[ 3.2.1]oct-2 -en-3-yl)-4 -fluoro-ph enyl ester MS (m/z): 346 (M+l). lHNMR (Methanol-d4,400 MHz) 5 7.10 (t, J= 9.6, 1H), 7.01 (m, 1H), 6.90 (m, 1H), 6.11 (d, J = 6.4, 1H), 3.50 (m, 1H), 2.85 (m, 2H), 2.62 (s, 2H), 2.55 (s, 6H), 2.48 (m, iH), 1.95 (m, 1H), 1.76 (m, 5H), 1.31 (d, J = 6.8,6H). Example 111 Synthesis of 2,2-dimethyl-propionic acid 3-(4-dimethylaminomethyl-bicyclo[3.2.1]oct- 2-en-3-yl)-phenyl ester hydrochloride Add H20 (18 mg, lmmol) and TMSC1 (75 mg, 0.69 mmol) to a solution of • 2,2-dimethyl-propionic acid 3-(4-dimethylaminomethyl-bicyclo[3.2.]]oct-2-en-3-yl)- phenyl ester (197 mg, 0.58 mmol) in 2-butanone (70mL). Stir the reaction mixture at ambient temperature for 2 hours. Evaporate the mixture under vacuum to afford 2,2-dimethyl-propionic acid 3-(4-dimethylaminomethyl -bicyclo[3.2.1]oct-2-en-3-yl)- phenyl ester hydrochloride as white solid (219 mg, Yield: 100%). !HNMR (400 MHz, Methanol-d4) S 7.38-7.42 (t,J= 16.4,1H), 7J3-7J5 (drJj = 7XJ* = 0A lti)t 6S6-638 (m, 2H), 6,23-6,23 (6, J= 6.S, JH>, 3.68-3.7J (d, J= 12.0,1H), 3.16-3.23 (t, J= 25.6,1H), 2.99-3.00 (m, 1H), 2.88-2.92 (d, J-14.8,6H), 2.65 (m, 1H), 2.60(rn, 1H), 1.95-1.98(nylH), 1.82-1.86 (m, 5H), 1.37 (s,9H). The following compounds may be prepared essentially by the method of Example 111. Ex. No. Chemical name Structure Physical data 112 Benzoic acid 3-(4-dimethylamin omethyl-bicyclo [3.2.1]oct-2-en-3 -yl)-pheny[ ester hydrochloride lH NMR (400 MHz, Methanol-d4) 8 8.19-8.21 (t, J = 8.0, 2H), 7.71-7.74 (t, J= 14.8, 1H), 7.57-7.61 (t, J = 15.6, 2H), 7.43-7.72 (t, J ■« 15.6, 1H), 7.13-7:22 (m; 3H), 6:25-6.27 (d,J = 6.8,1H), 3.71-3.74 (aV= 12.0, 1H), 3.19-3.26 (t, J= 25.6, 1H), 3.02-3.06 (m, 1H), 2.90-2.94 (d, J = 14.8, 6H), 2.65 (s, 2H), 1.95-1.98 (m, 1H), 1.83-1.87 (m, 5HK 113 2,2-DimethyI-pr opionic acid 3-(4-dimethylamin omethyl-bicyclo [3.2.1]oct-2-en-3 -yl)-5-fluoro-phe nyl ester hydroc hloride lH NMR (400 MHz, Methanol-d4) 5 6.94-6.96 (d, Jx = 3.6, J2= 2.0, 1H), 6.81-6.83 (m, 2H), 6.25-6.27 (4 ^ = 6.8, 1H), 3.65-3.68 (d, J = 10.8, 1H), 3.15-3.21 (t, J = 26.0, 1H), 2.88-2.93 (m, 7H), 2.66 (m, 1H), 2.58 (m, 1H), 1.82-1.96 (m, 6H), 1.37 (s,9H). For compounds of the formula Ic, below, Schemes F and G and Preparations and/or Examples 114-140 illustrate methods of preparing them. Example 114 Synmesisof3^2-dimethylaminomethyl-bicycb[3.2.1]oct-3-yl)-pheaol Add Pd/C (80 mg) to a solution of 3-(4-dimethylaminomethyI-bicyclo[3.2.1] oct-2-en-3-yl)-phenol (250 mg, 0.97 mmol) in MeOH (40 mL). Then stir the mixture at 25 °C for 12 hours under 45 PSI of H2. After filtration, Concentrate the solution under vacuum to afford 3-(2-dimethyLaminomethyl-bicyclo[3.2.1]oct-3-yl)-pheiiol as white solid (252 mg, Yield: 100 %). MS(m/z):260(M+J). The following compounds may be prepared essentially by the method of Example 114. Ex. No. Chemical name Structure Physical data 115 [3-(3-methoxy-phenyI)-bicyclo[3.2.1 - ]oct-2-ylmethyl]-dimethyl-amine MS (m/z): 274 (M+l). 116 3^2-dimethylaminomethyl-bicyclo[3 .2.1]oct-3-yl)-5-fluoro-phenol MS (m/z): 278 (M+l). 117 [3-(3 -fluoro-5 -methoxy-phenyl)~bicy clo[3.2.1]oct-2-ylmethyl3-dimethyl-a mine MS (m/z): 292" (M+l). 118 3 -(2-dimethylaminomethyl-bicyclo[3 .2.1 ]oct-3-yl)-4-fluoro-phenol MS (m/z): 278 (M+l). 119 [3-(2-fluoro-5-methoxy-phenyl)-bicy clo[3^.1]oct-2-ylmethyl]-dimethyl-a mine MS (m/z): 292 (M+l). Ex. No. Chemical name Structure Physical data 120 3 -(2-dimethylaminomethyl-bicyclo[3 .2. l]oct-3-yl)-5-methyl-phenol MS (m/z): 274 (M+l). 121 [3-(3-methoxy-5-methyl-phenyI)-bic yclo[3.2.1 ]oct-2-ylmethyl]-dimethyl-amine MS (m/z): ' 288 (M+l). Example 122 Synthesis of 3-(2-dmaethylamiiiomethylrbicycto[3.2.l]oct-3-yl)-phenol hydrochloride Add HjO (70 mg, 3.89 mmol) and TMSC1 (126 mg, 1.17 mmol) to a solution of 3-(2-dimethylaminomethyl-bicyclo[3.2.1]oct-3-yl)-phenol (252 mg, 0.97 mmol) in 2-butanone (30ml). Then stir the reaction mixture at ambient temperature for 12 hours. Evaporate the mixture under vacuum to give 3-(2-dimemyIaminomethyI-bicyclo [3.2.1]oct-3-yl)-phenol hydrochloride as white solid (286 mg, Yield: 99.8%). !H NMR (400 MHz, D20) S 7.04-7.07 (t, J= 10.4,1H), 6.58-6.72 (m, 3H), 2.80-2.91 (m, 1H), 2.52-2.54 (m, 3H), 2.44-2.48 (m, 3H), 2.33-2.41 (m, 1H), 2.20-2.29(m, 1H),2.11 (s, 1H), 1.99(s,2H), 1.36-1.47 (m,8H). The following compounds may be prepared essentially by the method of Example 122. Ex. No. Chemical name Structure Physical data 123 [3-{3-methoxy-phe nyl>bicyclo[3.2.1] oct-2-ylmethyl]-di methyl-amine hyd rochloride *H NMR (400 MHz, D20) 5 7.23-7.27 (t, 7=15.6, 1H), 6.80-6.90 (m,3H), 3.73 (s,3H), 2.95-3.01 (m, 1H), 2.54-2.62 (m, 6H), 2.38-2.42 (m,2H>, 2.22 (s, 1H), 2.12-2.14 (m,2H), 1.48-1.67 (m,8H). 1.24 3-(2-dimethyIamin omethyl-bicyclo[3 .2.1]oct-3-yt)-5-flu oro-phenol hydroc hloride lHNMR(400MHz,D2O) 5 6.55-6.49 (m,2H), 6.41-6.38 (4-flu oro-phenol hydroc hloride 'HNMR^OOMHz^O) 8 6.91-6.83 (m,lH), 6.74 (s, 1H), 6.62-6.49(01,111), 3.03-2.94 (m, 1H), 2.49 (s, 4H), 2.42-2.35 (m, 2H), 2.19-2.08 (m,6H), ' 1.63-1.40 (m,7H). 127 [3-(2-fluoio-5-met hoxy-phenyl)-bicy clo[3.2.1]oct-2-yl . methylj-dimethyl-amine hydrbchlori de *H NMR (400 MHz, D20) 6 6.98-6.86 (m, 1H), 6.76 (s,lH), 6.75-6.74 (m, 1H), 3.68 (s, 3H), 3.04-2.98 (m, lH),2.81(s,lH), 2.64-2.55 16.0,1H), 7.17-7.18 (t, J= 4.4,1H), 7.11-7.13 (m,iH), 6.76-6.79 (d,J= 10.0,1H), 3.23-3.25' (m, 1H), 2.68-2.69 (m, 7H), 2.14-2.17 (m, 1H), 2.04-2.09 (m, 1H), 1.76-1.81 (m, 1H), 1.62-1.64 (m, 1H), 1.47-1.49 (m, 1H), 1.11-1.16 (m, 1H), 0.93-1.05 (m, 1H), 0.73-0.84 (m, 1H), 0.50-0.53 (m,lH). The following compounds may prepared essentially by the method of Example 153. £x. No. Chemical name Structure Physical data 154 3 -Dimethylaminomet hyl-2-(3^methoxy-phe nyl)-)3icyclb[4.1.0]he ptan-2-ol hydrochlori de C l OH CIH iHNMR(400MHz, Methanol-d4) 8 7.23 (m, lH),7.17(m, m),7M(mt lH),6.78(m, lH),3.72(s, 3H),2.95 (m, 1H), 2.60-2.71 (m, 7H), 2.16 (m,lH), 2.05 (m, 1H), 1.80 (m,lH), 1.65 (m, 1H), 1.48 (m, 1H),1.15 (m,lH), 1.01 (m,lH), 0.67 (m, 1H), 0.50 (m, 1H). 155 3-Dimethylaminomet hyl-2-{3-fluoro-5-met hoxy-phenyl)-bicyclo [4.1.0]heptan-2-ol hydrochloride I U OH CIH 'HNMR(400MHz, MethanoI-d4) 8 7.08 (d, J = 1.6,1H), 7.00 (m,lH), 6.62 (raJH), 3.82 (s,3H), 3.02 (m,lH), 2.75 (m,7H), 2.23 (m,lH), 2.10 (m,lH), 1.8I(m,lH),1.73(ni,lHX 1.62 (m,lH), 1.26 (m,lHX 1.12 (m,lH), 0.85 (m,lHX 0.64 (m, 1H). Ex. No. Chemical name Structure Physical data 'HNMR^OOMHz, Methanol~d4) 8 7.10-7.12 (d,J= 8.0,1H), 6.92 (s,lH), 3-Dimethylaminomet 6.75-6.77 (d,J= 8.0,1H), hyl-2-(5-methoxy-2- 3.79 (s,3H), 3.12 (s,2H), 156 methyl-phenyl)-bicycl o[4.1.0]heptan-2-ol JL [OH OH 2.85 (s,6H), 2.59 (s, 3H); 2.47 (s, 1H), 2.15-2.16 (m, hydrochloride KKJ ' ' 1H), 1.63-1.80 (m,3H), 1.41-1.44 (m,lH), 1.25-1.29 (m,lH), 0.70-0.71 (m,lH), 0.25-0.26 (m,lH). Example 157 Synthesis of 3-dimethylaminmomethyl-2-(3-fluoro-5-hydroxy-phenyl)-bicyclo[4.1.0]heptan-2-ol Add a solution of t-BuLi (19.4 mL, 25.2 mmol) via syringe to a solution of (3-bromo-5-fluoro-phenoxy)-tert-butyl-diniethyl-silane (6.99 g, 22.9 mmol) in THF (100 mL) at -78 °C under N2. After being stirred at -78 °C for 1 hour, add dropwise a solution of 3-dimethylaminomethyl-bicyclo[4.1.0]heptan-2-one (2.55 g, 15.3 mmol) to the reaction mixture and stir the reaction mixture at -78 °C for additional 2 hours. Quench the reaction with saturated NH4CI solution (30 mL). Extract the resultant aqueous mixture with EtOAc (100 mL x 3). The combined organic layers are washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated under vacuum. Treat the residue with TBAF (6.00 g, 22.9 mmol) in CH2C12 (80mL) at ambient temperature for 4 hours. Concentrate the mixture, and purify the residue by preparative HPLC to give 3-dimethylaminomethy l-2-(3-fluoro-5-hydroxy-phenyl)-bicyclo[4.1.0] heptan-2-ol as white solid (592 mg, yield: 13.9%). MS (m/z): 280 (M+l). The following compounds may be prepared essentially by the method of Example 157. Ex. No. Chemical name Structure Physical data 158 3-Dimethylaminomethyl-2-(2-fluoro-5-hydroxy-ph enyl)-bicyclo[4.1.0]hepta n-2-ol MS (m/z): 280 (M+l). 159 3-Dimethylaminomethyl-2-(3-hydroxy-5-methyl-p henyl)-bicyclo[4.1 .Ojhept an-2-dl fSoH MS (m/z): 276 (M+l). Example 160 Synthesis of 3^imethyIaminomethyl-2-(3-fluoro-5-hydroxy-phenyl)-bicyclo[4.1.0] heptan-2-ol hydrochloride F Add H20 (18 mg, 1.0 mmol) and TMSC1 (92 mg, 0.857 mmol) to a solution of 3-dimethylaminomethyl-2-(3-fluoro-5-hydroxy-phenyl)-bicyclo[4.1.0] heptan-2-ol (218 mg, 0.781 mmol) in 2-butanone (70 mL). Then stir the reaction mixture at room temperature for 2 hours. After removal the solvent by evaporation, wash the residue with EtOAc (3 mL x 2) to give 3-dimerayiammomemyl-2-(3-fluoro^^ as white solid (72 mg, Yield: 67.8%). 'H NMR (400 MHz, D20) S 6.93 (s, 1H), 6.87-6.89 (d, J = 9.6,1H), 6.42-6.58 (m, 1H), 3.32-3.33 (t, J= 3.2,1H), 2.98-3.04 (m, 1H), 2.77 (m, 6H), 2.22-2.23 (m, 1H), 2.06 (m, 1H), 1.81-1.85 (m,2H), 1.61-1.71 (m, 1H), 1.17-1.21 (m, 1H), 1.08-1.10 (m, 1H), 0.83-0.86 (m, 1H), 0.56-0.60 (m, 1H); The following compounds may be prepared essentially by the method of Example 160. Ex. No. Chemical name Structure Physical data 161 'HNMR(400MHz, Methanol-d4) S 7.27-7.30 (m, 3-Dimethylamino 1H), 6.91 (m,lH), 6.69-6.73 methyl-2-(2-fluoro (m, 1H), 3,06-3.11 (m,lH), -5 -hydroxy-phenyl 2.76-2.86 (m, 7H), 2.46-2.54 )-bicyclo[4.1.0]he ptan-2-ol hydroch (m, 1H), 2.20-2.26 (m, 1H), 1.83-1.87 (m,lH), 1.64-1.71 loride (m, 1H), 1.52-1.57 (m, 1H), 1.19-1.21 (m, 1H), 1.02-1.14 (m, 1H), 0.73-0.79 (m, 1H), 0.59-0.63 (m, 1H). 162 1HiSIMR(400MHz, — Methanol-d4) 5 6.95 (s, 1H), 6.91 (s, 1H), 6.56 (s, 1H), 3 -Dimethy lamino 2.97-3.04 (m, 1H), 2.78-2.82 (d, methyl-2-(3-hydro J/= 13.2, Jf= 2.0,1H), 2.74 (s, xy-5 -methyl-phen 6H), 2.31 (s, 3H), 2.20-2.27 (m, yl)-bicyclo[4.1.0]h eptan-2-ol hydroc 1H), 2.05-2.10 (m,lH), i:80-1.87(m,lH), 1.68-1.76 hloride (m,lH), 1.55-1.60 (m, 1H), 1.17-1.21 (m,lH), 1.06-1.12 (m, 1H), 0.86 (m, 1H), 0.58 (m, 1H). Scheme J Example 163 Synthesis of 2,2-dimethyl-propionic acid 3-(3-dimethylaminomethyl-2-hydroxy-bicyclo [4.1.0]hept-2-yl)-5-fluoro-phenyl ester Stir a mixture of 3-dimethylarninomethyl-2-{3-fluoro-5-hydroxy-phenyl)-bicyclo [4.1.0]heptan-2-ol (295 mg, 1.06 mmol), 2,2-dimethyI-propionyl chloride (153 mg, 1.27 mmol) and triethyl-amine (321 mg, 3.18 mmol) in CH2CI2 (40 mL) at ambient temperature for 5 hours. Quench the mixture with 10 mL of H2O. Separate the aqueous layer off, and concentrate the organic layer under reduced pressure. Purify the residue by preparative TLC to give 2,2-dimethyl-propionic acid 3-(3-dimethylaminomethyl-2- hydroxy-bicyclo [4.1.0]hcpt-2-yl)-5-fluoro-phenyl ester as white solid (228 mg, Yield: 59.2%). MS (m/z): 364 (M+I). lHNMR(400 MHz, Methanol-d4) S 7.25-7.28 (d, Ji = 10.4, J2-= 1.6,1H), 7.14 (s, 1H), 6.76-6.78 (d,./i = 9.2, J2= 2.4, 1H), 2.37-2.46 (m,_lH), 2.15-2.19 (m, 7H), 1.99-2.03 (dtJ= 13.2, 1H), 1.82(m,2H), 1.53-1.68 (m,2H), 1.37 (s,9H), 1.17 (m, 1H), 1.01-1.06(m, 1H), 0.75-0.81 (m, 1H), 0.48-0.50 (m,lH). The following compound may be prepared essentially by the method of Example 163. Ex. Chemical name Structure Physical data No. ■■- - - 2,2-Dimethyl-prop MS(m/z):364(M+l) 1HNMR(400MHz, ionic acid 3-(3-di Methanol-d4) 8 7.50-7.53 (m, 164 methylaminometh 1H), 7.06-7.15 (m,lH), 6.96-7.00 (m,lH), 2.41-2.44 - yl-2-hydroxy-bicy • cIo[4.1.0]hept-2-yI )-4-fluoro-phenyl (m,lH), 2.17-2.22 (m,2H), 2.02 (s, 5H), 1.98-2.02 (m, 2H), ester 1.80-1.85(m, 1H), 1.52-1.64 (m,2H), 1.38 (s,9H), 1.13-1.22 (m, 1H), 1.02-1.06 (m, IH), 0.70-0.72 (m, 1H), 0.59-0.636 (m,lH). For compounds of the formula Ie, below, Scheme K and Preparations and/or Examples 165-176 illustrate methods of preparing them. Preparation 165 (lR,2R,5S)-2,6,6-trimethylbicyclo[3.1.1Jheptan-3-one Jones reagent: add a mixture of 9 ml of H2SO4 and 40 ml of H2O to a solution of Cr2O3(15.0g,0.15mol)inH2O(20mL)at 00C. - - Add dropwise the above Jones reagent to a solution of (lR,2R,3R,5S)-2,6,6- trimethylbicyclo[3.1.1]heptan-3-ol (23.1 g, 0.15 mol) in acetone (l00mL) over a period for 2 hours at 0 °C. Stir the resultant mixture for additional 1 hour. Dilute the mixture with 100 mL of water and then extract the aqueous mixture with ether (50 mL X3). The combined organic layers are washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated under vacuum to give crude (lR,2R,5S)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-one as pale yellow oil (21.3 g, yield: 93.4%), MS (m/z): 151 (M-l). The following compound may be-prepared essentially by the method of Preparation 165. Prep No. Chemical name Structure- Physical data .166 (1 S,2S,5R)-2,6,6-trimeth ylbicyclo[3.1.1 ]heptan-3-one MS(m/z):151(M-l). Preparation 167 (1 R,2R,4S,5S)-2,6,6-trmiemyl-4-(memyl(phenethyl)amino)methyI)bicyclo[3.1.1 ]heptan-3-or Stir a mixture of (lR2R,5S)2,6,6-trimethylbicyclo[3.1.1]heptan-3-one (7.6 g, 50.0 mmol), (HCHO)n (1.8 g, 60.0 mmol), N-methyl-2-phenylethanamine (6.75 g, 50.0 mmol) and 5.0 mL of cone. HC1 in MeCN (50 mL) at 70 °C for 3 hours. After removal of the solvent under vacuum, dissolve the residue in H20 (30 mL) and washed with EtOAc (20 mL X 2). Basify the aqueous solution with K2CO3 to pH = 9 and extract the resultant mixture with EtOAc (30 mLx3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated under vacuum to give crude product as brown oil, which was further purified by silica gel chromatography to give (lF^2R,4S,5S>2,6,6-trmie%M-((memyl(phenemyI)amino) methyI)bicycle[3.1.1]heptan-3-one as pale yellow oil (9.24 g, yield: 61.8%), MS (m/z): 300 (M+l). The following compound may be prepared essentially by the method of Preparation 167. Prep No. Chemical name Structure Physical data 168 (lS£S,4R,5R)-2,6,6-trim emyl^(methyl(pheneth yl)amino)methyl)bicycIo[ 3,l.l]heptan-3-one ..'**r»-^Nr^3-(3-hydroxyphenyl)-2,6,6-trmiemyl-4-((methyl(phenemyl)ammo)m g, yield: 6.9%), MS (m/z): 394 (M+l). The following compound may be prepared essentially by the method, of Example 169. Ex. No. Chemical name Structure Physical/data 170 (lR^R,3S,4S,5S)-3-(3-m ethoxyphenyl)-2,6,6-trim ethyl-4-((methyl(pheneth yl)amino)methyl)bicyclo[ 3.1.1]heptan-3-ol O— MS (m/z): 408 (M+l). 171 (lS,2S,3R,4R,5R)-3-(3-h ydroxyphenyl)-2,6,6-trim ethyl-4-((methyl(pheneth yl)amino)methyl)bicyclo[ 3.1.1]heptan-3-ol MS (m/z): 394 (M+l). Ex. No. Chemical name Structure Physical data 172 (lS,2S,3R,4R,5R)-3-(3- 0 methoxyphenyl)-2,6,6-tri methy!-4-((methyl(phene thyl)amino)methyl)bicycl MS (m/z): 408 (M+l). o[3.1.1]heptan-3-ol . %' Example 173 (lR,2R,3S,4S,5S)3-(3-hydroxyphenyl)-2,6,6-trim^ yclo[3.1.1]heptan-3-ol hydrochloride Add H20 (4 mg, 0.25 mmol) and TMSCt (27 mg, 0.25 mmol) to a solution of ((lR,2R,3S,4S,5S)-3-(3-hydroxyphenyl)-2,6,6-trim yclo[3.1.1]heptan-3-oI (100 mg, 0.25 mmol) in 2-butanone (5 mL). Stir the reaction mixture at room temperature for 3 hours. After removal solvent by evaporation, wash the residue with EtOAc (1 mL X2) and dry under vacuum to give(lR,2R,3S,4S,5S)-3-(3-hydroxyphenyl>2,6,6-trimethyl -4^(methyl(phenethyl)amino)methyl)bicyclo[3.1. l]heptan-3-ol hydrochloride (93 mg, Yield: 85.3%) as white solid. 'H NMR (400 MHz, DzO) 8 7.21 -7.32 (m, 7H), 7.97-7.99 (d, J= 7.2,1H), 6.71-6.78 (dd, Jt = 8.0, J2 = 22.0,1H), 2.86-3.33 (m, 5H), 2.43-2.68 (m, 7H), 2.11-2.20 (m, 2H), 1.73-1.75(m,lH), 1.23-1.25 (d, J- 5.6,3H), 1.04-1.05 (d, .7=4.4,3H), 0.69-0.71 (d,,7= 5.6,3H). [a]$ = -8.6 (c= 1.4 mgtoiL, MeOH). The following compounds may be prepared essentially by the meihod of Example 173. Ex. No. Chemical name Structure Physical data 174 (lS,2S,3R,4R,5R)-3-(3-m ethoxyphenyI)-2»6,6-trim elhyl-4-((methyl(pheneth y l)amino)methyl)bicyclo [ 3.1.1]heptan-3-ol hydrochloride p— ^\ OH C1H 1.* *.i f 'HNMR^OO MHz, DzO) 5 7.02-7.26 (m, 7H), 6.74-6.86 (m,2H), 3.64-3.66 (d, 7= 10.4, 3H), 2.76-3.22 (m, 5H), 2.32-2.53 (m, 7H), 2.02-2.14 (m, 2H), 1.64-1.67(m,lH), 1.14-1.56 (d, J = 6.8,3H), 0.95-0.97 (d, J= 6.4,3H), 0.63 (s,3H). [a]?J = -16.1 (c= 6.4 mg/mL, MeOH) 175 (lS,2S,3R,4R,5R)-3-(3-h ydroxyphenyl)-2,6,6-trim emyl-4-((memyi(pTaeneth yl)amino)methyl)bicyclo[ 3.1.1]heptan-3-ol hydrochloride OH ^AjOH CIH MS(m/z):394(M+l). [a]?} = 9.3 (c = 4.5 mg/mL, MeOH) Ex. No. Chemical name Structure Physical data 176 (lS^S,3R,4R^R>3-(3- methoxyphenyl)-2,6,6-tri MS(m/z):408(M+l). methyl-4-((methyl(phene thyl)amino)methyt)bicycl [a]$ = 14.3 (c = 6.0 mg/mL, o[3.U]heptan-3~ol MeOH) hydrochloride* * A. - - For compounds of the formula If, below, Scheme L and Preparations and/or Examples 177-180 illustrate methods of preparing them. Preparation 177 Synthesis of (2,3,3a,6,7,7a-hexahydro~lH-inden-4-yloxy)ttim&thy}^lme Add dropwise hexahydio-lH-inden-4(2H)-one (1.6 g, 11.6 mmol) in dry THF (5 mL) to a solution of LDA (23.2 mL, 23.2 mmol) in THF (30 mL). Stir the reaction mixture for 30 min and then add dropwise TMSC1 (3.5 g, 32.0 mmol) to the reaction mixture. Stir the resultant solution for additional 1 hour. Pour ihc mixture into ice water (50 mL) and extract the aqueous mixture with EtOAc (50 mL x 3). The combined organic layers are washed with brine, dried over MgSC>4, filtered and concentrated in vacuo to afford crude (2,3f3a,6,7,7a-hexahydro-lH-inden-4-yloxy) trimethylsilane (2,45 g, 100 %) as yellowish oil, MS (m/z):209(M-l). Preparation 178 5^(dimethylanmio)memyl)hexahydro-lH-iriden-4(2H)-one Add (2,3,3a,6,7,7a-hexahydn>-lH-inden-4-yk>xy) trimethylsilane (2.45 g, 11.6 mmol) to a cooled suspension of N,N-dimemylme&yleneiminium iodide (2.78 g, 15.0 mmol) in CH2CI2 (60 mL) at 0 °C. After being sthTed for overnight at ambient temperature, dilute the reaction mixture with 2 N HCI (20 mL). After removal of organic layers, wash the aqueous layer with EtOAc (30 mL x 3) and then basify withNaOH to PH = 10. Extract the resultant mixture with EtOAc (50 mL x 4). The combined organic layers are washed with brine, dried over Na2SO4, filtered and concentrated in vacuo to afford 5^(dirnemylamino)methyl)hexahydro-lH-inden-4(2H>one (623 mg, 27.5 %) as oil, MS (m/z): 196 (M+I). __ Example 179 5^(dimemylammo)memyl)^^34iydroxyphenyi^^ Add a solution of f-BuLi (2.1 mL, 3.07 mmol) via syringe to a solution of 3-bromo-phenol (569 mg, 3.076 mmol) in THF (50 mL) at -78°C under N2. After being stirred at -78 °C for 1 hour, add a solution of 35-((dimemylarnino)methyl) hexahydro-lH-inden-4(2H)-one (300 mg, 1.54 mmoi) in THF (2 mL) to the reaction mixture and stir the reaction mixture at -78 °C for additional 2 hours. Quench the reaction mixture with saturated NH4CI solution (30 mL). Extract the aqueous resultant mixture with EtOAc (50 mL x 3). The combined organic layers are washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated under vacuum. Purify the residue by Preparative HPLC to give 5<(dimethylarnino)memyl)^(3-hydroxyphenyl) octahydro-lH-inden-4^! (92 mg, yield: 19.7%). MS (m/z): 290 (M+l). Example 180 ^^(dimethylarnm^e^ Add H2O (10 mg, 0.54 mmol) and TMSC1 (35 mg, 033 mmol) to a solution of 5-((a%iethylammo)m^y!^^ mmoi) m 2-butanone (10 mL). >nen sfa me mixture at room temperature for 12 hours. Evaporate the mixture under vacuur^ to give 5-((dimemylamino)methyl)- ^(S-hydroxyphenyl^^^ydro^H.ind^^^iijy^^oride as a mixture of 4 diastercoLsomers (91 mg, Yield: 100%), ~~ Example 181 (+)^lS^R13R,5R)-2^(dimemylarmno)memyl)-3<3-hydroxyphenyl)bicyclo[3.2.1]o (-)-(lR,2S,3S,5S)-2 ^(cUmemylammo)memyl)-3^3-hydroxyphenyl)bicyclo[3.2.1]octan-3-ol. Separate 0.5 g of 2-((dimethyIamino)methyl)-3-(3-hydroxyphenyl)bicyclo[3.2.1] bctan-3-ol (1.82 mrnol) by SFC to afford (+KlS,2R,3^5R)-2~((dimeth^amino) methyl)-3-(3-hydroxyphenyl)bicycto[3.2.i3octan-3-ol (8 mg, Yield: 3.2%; MS (m/z): 276 (M+l)) and (-)-(lR£S3S,5S)-2-((dmethylam^^ (135 mg, Yield: 54.0%; MS (m/z): 276 (M+l)) as white solids. The relative configuration of two enantioisomers is confirmed by 2D NMR and the absolute configuration of the two enantioisomers is determined by x-ray analysis. (+)-Enantioisomers show better biological activity than (-)renantioisomer in bioassay(s). Example 182 (S)-3<(lS,2R,3R,5R)-2-((dimewylammo)memyl^ 2-phenylpropanoate hydrochloride Stir a solution of (S)-2-phenylpropanoic acid (300 mg, 2.0 mmol) in 5 mL of oxalyl chloride for 3 hours at room temperature. After removal of solvent under vacuum, (S)-2-phenylpropanoyl chloride is obtained as pole yellow oil. Dissolve the oil in 10 mL of CH2C12. Add (lS,2R,3R,5R>2-((dimemylamino)memyl)-3-(3-hydroxyphenyl) bicyclo[3.2.1] octan-3-ol (400 mg, 1.45 mmol) and Et3N (293 mg, 2.9 mmol) to me solution. Stir the resultant mixture at room temperature for additional 3 hours. After addition of 20 mL of water, basify the mixture with K2CO3 to pH = 10, and extract the aqueous mixture with EtOAc (20 mL X 3). The combined organic layers are washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated under vacuum. Purify the residue by silica gel chromatography (GrfeCkrMeOH = 30:1) to afford (S>3^(lS,2R,3R,5R)-2-((dimethyIai^ -3-yl) phenyl 2-phenylpropanoate (500 mg, 84.7%; MS (m/z): 408 (M+l)) as yellow oil. Stir (S)^(lS,2R,3R,5R)-2^(dmemylammo)me% 2-phenylpropanoate (250 mg, 0.61 mmol) with H20 (11 mg, 0.61 mmol) and TMSC1 (66 mg, 0.61 mmol) in 2-butanone (5 mL) for 3 hours. Collect the precipitate by filtration to afford (S)-3-(lS,2R,3R,5R)-2^(dime%lamino)me%l)-3-hydn)xybicyclo[3^.1]octBn-3-yl)pheiiyl 2-phenylpropanoate hydrochlorid (215 mg, Yield: 79.3%) as.white solid. The absolute configuration of its hydrochloride salt form was confirmed by x-ray analysis. 'HNMR(400 MHz, DMSO) 8 9.81 (br, 1H), 7.31-7.41 (m, 7H), 7.14 (s, 1H), 6.87-6.90 (m, 1H), 5.01 (s, 1H), 4.08-4.10 (m, 1H), 3.02-3.08 (m, 1H), 2.42-2.58 (m, 4H), 2.12-2.26 (m, 6H), 1.90-1.99 (m,2H), 1.75-1.80 (m,2H), 1.51-1.59 (m,6H). The following compound may be prepared essentially by the method of Example 182. Ex. No Chemical name Structure Physical data — *H NMR (400 MHz, DMSO) 8 (S>3-((lR,2S,3S,5S)-2-( 9.78 (br, 1H), 7.34-7.47 (m, 7H), (dimethylamino)methyl) 7.23 (s, 1H), 6.91-6,93 (m, 1H), -3-hydroxybicyclo[3.2.1 rvW^ 5.14 (s, 1H), 4.13-4.18 (m, 1H), 183 ]octan-3-yl)phenyl 3.09-3.15 (m, 1H), 2.48-2.65 (m, i 2-phenylpropanoate 4H), 2.17-2.32 (m, 6H), 1.97-2.06 hydrochloride (m,2H), 1.81-1.86 (m,2H),. ' 1.49-1.66 (m,6H). Example 184 3-(4-d^emylaminomethyI-bicyclo[3.2.1]oct-2-en-3-iyl)-phenoIand 3-((lS,5R>2-((m^emyIamino)methyl)bicyclo[3.2.1]oct-2-en-3-yl)phenol Add TsOH (5.0 g, 29.1 mmol) to a solution of 2-dimethylaminometiiyl- 3-<3-hydroxy-plieiiyl)-bicyclo[3.2.1]octan-3-ol (4.8 g, 17.5 mmol) in toluene (150 mL). Heal the reaction mixture to reflux for 2 hours and then quench the reaction by addition of saturated aqueous K2CO3 (20 mL). Extract the aqueous layer with EtOAc (60 mL x 3); The combined organic layers are washed with brine, dried over Na2SO4 and evaporated under vacuum. Purify the residue by preparative HPLC to yield 3^4-dimemylaminomethyl-bicyclo[3^.1]oct-2-en-3-yl)- phenol (2.27 g, 50.2 %;.MS (m/z): 258 (M+l)) and . 3^2^(d%iemylamino)methyl)bicyclo[3.2.1]oct-2-en-3-yl) phenol (517 mg, 11.5 %; MS (m/z): 258 (M+l)) as white solid. Two isomers show comparable biologicaf activity in bioassay. For compounds of the formula Ig, below, Scheme M and Preparations and/or Examples 185-187 illustrate methods of preparing them. Preparation 185 5-dimethylaminomcthyl-spiro[2.5]octan-6-one Stir a mixture of spiro[2.5]octan-6-one (252 mg, 2.03 mmol), (HCHO)n (61 mg, 2.03 mrriol), dimethylamine hydrochloride (166 mg, 2.03 mmol) and 0.3 mL of cone. HC1 in MeCN (30 mL) at 60 °C for 6 hours. Quench the reaction with saturated aqueous NH4CI solution (15 mL). Easily the aqueous solution with K2CC>3 to pH - 9. Extract the aqueous mixture with EtOAc (30 mL x 2). The combined organic layers are washed with brine (15 mL), dried over N&2SO4, filtered, and concentrated under vacuum. Purify the residue by silica gel chromatography (CH2Cl2:MeOH = 30:1) to afford 5-Dimethylaminomethyl-spiro[2.5]octan-6-<)ne as brown oil (142mg, yield: 38.4%). MS (m/z): 182 (M+l). Example 186 5Kiimemylanimomethyl^-(2-fluoro-5-hydroxy^ Cool a solution of (3-bromo-4-fluoro- phenoxy)-tert-butyl-dimethyl-silane (472 mg, 1.547 mmol) in THF (40 mL) to -78 °C under N2. Then add dropwise a solution of «-BuLi (0.63 mL, 1.547 mmol) in hexane via syringe to the reaction solution. After being stirred at -78 °C for 2 hour, add dropwise a solution of 5-Dimemylaminomethyl-spiro[2.5]octan-6-one (70 mg, 0.387 mmol) in THF (1 mL) to the reaction mixture and stir the mixture at -78 °C for additional 2 hours. Quench the reaction with 20 mL of diluted HC1 (2N), and stir at ambient temperature for 2 hours. Basify the resultant mixture with K2C03 to pH = 9, and extract with EtOAc (30 mL X 2). The combined organic layers are washed with brine, dried over Na2SO4, filtered, and concentrated under vacuum. Purify the residue by silica gel chromatography (CH2CI2 to CI^CfoMeOH =10:1) to afford 5-dimethylanunomethyl ^-(2-fluoro-5^ydroxy-phenyl)-sph*o[2.5]octan-6-ol as white solid(41mg, yield: 363%). MS (m/z): 294 (M+l), Example 187 5-dimethylammomemyl-6-(2~fluoro-5-hydroxy-phenyl)-spiro[2.5ioctan -6-0I hydrochloride Add H20 (9 mg, 0.500 mmol) and TMSC1 (18 mg, 0.167 mmol) to a solution of 5-liimethylantinomemyl^2-fluoro-5-hydroxy-phenyI)-spiro[2.5]octan-6-ol (41 mg, 0.139 mmol) in 2-butanone (30 mL). Stir the mixture at 0°C for 2 hours/Concentrate the mixture under vacuum to give 5-dimethylaminomethyl-6-(2-fluoro -5-hydroxy-phenyl)-spiro[2.5]octan-6-ol hydrochloride as white solid (46 mg, Yield: 100%). 1HNMR(400MH2,D2O)67.13-7.15 (d, J/ = 6.8, h = 32,1H), 6.93-6.98 (d, Ji = 12.0, J2 « 8.8,1H), 6.69-6 J3 (m, 1H), 3.05-3.10 (m, 1H), 2.65-2.76 (m, 8H), 2.44-2.45 (m, 1H), 2.27-2.35 (m, 2H), 1.70-1J4 (m, 1H), 0.96-0.98 (m, 1H), 0.79-0.82 (m, 1H), 0.45 (m, 1H). Mu opioid agonists, such as morphine, are well known to control pain (Tschenkte et al.y Tapentadol Hydrochloride - Analgesic, Mu-opioid receptor agonist, Noradrenaline reuptake inhibitor. E. Drugs Fut 2006,31(12); 1053). However, mu opioid agonists also can cause several undesired side effects such as-nausea, emesis, constipation, mental clouding, and respiratory • depression. In addition, use of opioids for an extended period of time (as is needed in chronic pain) can result in physical dependence and addiction. Tramadol, a mu-opioid agonist, has not been associated with clinically significant side effects such as respiratory depression, constipation, or section (Id.). In addition, extended use of Tramadol does not lead to tolerance, dependence, and addiction (Id.). Tramadol is believed to exert its chronic pair relief through a combination of three mechanisms of action, ma opioid agonism and serotonin and norepinephrine reuptake inhibition (Raffa et aL, Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Tker. 1992 Jan; 260(l):275-85). Because Tramadol relieves pain through a combination of mechanisms of action it is able to relieve pain even though it is a much less potent mu opioid receptor agonist compared to morphine. The reason for the better side effect profile of Tramadol as compared to morphine is believed to be a result of Tramadol's lower affinity for the mu opioid receptor. A molecule that, like Tramadol, controls chronic pain by multiple mechanisms of action is desired, and a compound which possessed a favorable side effect profile, particularly as compared to morphine, and that also was longer acting was sought. Preferably, a molecule that needed to be administered at most 1 time per day for extended pain relief is sought. Molecules that are mu opioid agonists and also norepinephrine and/or serotonin reuptake inhibitors are preferably selected for evaluation in the rat tail flick model. In order to be selected for the rat tail flick model the compound needs to demonstrate an EC50 of less than 50 micromolar in a functional assay for mu opioid receptor activation. In addition, the active species needs to demonstrate an IC50 of less than 500 micromolar in a. functional assay for inhibition of norepinephrine and/or serotonin reuptake. Activity of the corresponding phenols are used to select ether and ester prodrugs for evaluation in the rat tail flick model. The Tail Flick Assay, based upon the methods of D'Amour & Smith (J. Pharmacol. Exp. Therap., 72; 74-79,1941), is used to measure loss of pain sensation in the rat tail, allowing the experimenter to screen drugs for analgesic effect. Since then, the method has been used in a number of publications. For example, it was used to evaluate the analgesic effect of O-alkyl derivatives of tramadol by Liming Shao and Michael Hewitt etc. (Boiorganic & Medicinal Chemistry Letters, .18:1674-1680,2008). A Tail Flick Unit is used to measure tail flick latency in response to heat. The unit consists of an infrared (I.R.) source (50W bulb) with adjustable intensity that is focused through a flush mounted window on the upper panel of the unit and onto the rat tail. Once J.R. source is focused on the rat tail and turned on, a timer starts. When the thermal threshold for pain is reached and the rat flicks its tail, the I JR. source automatically shuts off and the timer stop, displaying the latency time. on the day of experiment, the animals are tested to determine baseline latency. Each rat is given one test to determine latency to tail flick with a cut off 10 seconds. Baselines are recorded and those animals with a baseline latency of 2-5 seconds are used in the experiment. Aniinals are divided into several groups according to the baseline latency. The Tail-flick latencies are measured at different timepoints for up to 180 minutes after adrninistration of vehicle or test articles. If treatment group continues to display pain control after 180 minutes, additional measurements are taken every 60 minutes until pain control is no longer observed. I.R. Source is set at 40 units (determined to elicit tail flick response in desired 2-5 seconds in naive animals). A cut off time of 10 seconds is set to avoid tissue damage, in the event that the animal does not flick its tail. Test articles or vehicle are adrninistered by intravenous (IV) injection through the tail vein or by oral gavage at time 0. Animals are gently restrained and held on top of a tail flick unit. The tail is then wiped clean with a cotton square and placed over the I.R. source so that the beam is focused at approximately midway the length of the tail. After the rat is in position, the I.R. source is turned on. When the thermal threshold for pain is reached, the rat flicked its tail and the I.R. source automatically shuts off. Latency time (in seconds) is then recorded. Data are recorded and graphed as %MPE (Maximum Possible Effect). % MPE is calculated using the following formula: % MPE = [(Test latency - Baseline latency) / (Cut off latency (10 sec's) - Baseline latency)] *100 ■* > Compounds were administered by the IV route in 20% 2-hydroxypropyl-beta-cyclodextrin (20% HP-p-CD). The dose levels of test article were 2.5,5, or20mg/kg. Examples2,3,13,40,77,78,114, and Tramadol provided at least 50% MPE at 20 mg/kg. Compounds 5,8,17,105,107,148,158, and 159 provided at least 50% MPE at 5 mg/kg. Compounds 82, 84, and 116 provided at least 50% MPE at 2.5 mg/kg. Compounds were administered by oral gavage in 0.5% methylcelrulose at 20 or 30 mg/kg. Examples 2,3,13,115, and Tramadol provided at least 50% MPE at 30 mg/kg. Compounds 5,39,65,106, and 115 provided at least 50% MPE at 20 mg/kg. The data above supports the contention the compounds are useful in controlling pain. WECLAIM: 1. A compound, or salt thereof of formula I: wherein A is R1 is hydrogen, C1-C5 alky!* C1-C5 alkoxy, C1-C5 haloalkyl C1-C5 alfcanol, -(C1-C5 alkyl)phenyl, or phenyl, or a group of the formula -C(0}-R12, where R12 may be C1-C5 alkyl, C1-C5 alkoxy, C1-C5 haloalkyl, C1-C5 alkanol, -(C1-C5 alkyl)phenyl, or phenyl; R2 is hydrogen, C1-C5 alkyl,- C1-C5 alkoxy, halogen, C1-C5 haloalkyl, or C1-C5 haloalkoxy; R3 is hydrogen, C1-C5 alkyl, C1-C5 alkoxy, halPgen, C1-C5 haloalkyl, or C1-C5 haloalkoxy, R4 is hydrogen, C1-C5 alkyl, or-(C1-C5 alkyl)r>henyl; R5 is hydrogen, C1-C5 alkyl, or -{C1-C5 alkyl)phenyl; R6 is hydrogen, hydroxy, or is absent; R7 is hydrogen; R8 is hydrogen or methyl; R9 is hydrogen or methyl; R10 is hydrogen; R11 is hydrogen or C1-C5 alkyl; or R7 and R10 combine to form-CH2-or-{CH2)2S or R8 and R9 combine to form a cyclopropyl group with the carbon to which they are attached; or R10 and R11 combine to form -CH2~ or -(CH2)3- 2. The compound of claim 1 wherein A is selected from 3. The compound of claim 2 of the formula Ia: 4. The compound of claim 3 wherein it is 2-dimemylarm^omemyl-3-(3-methoxy^^ 2-dimemylamuMmemyl-3^3-fluoro-5-m 2-dimethylammomemyl-3-(5-memoxy-2-trifluoromemoxy-phenyl)-bicyclo 2-dimemyIammomemyl-3^2-fluoro-5-memoxy-phenyI)-bicyclo[3.2J]c^an-3-o!; 2-dimemylanmiomemyl-3^4-fluoro-3-memoxy-ph^ 2-dimethylaminomethyl-3^2-fluoro-3-methoxy-phenyl)-bicyclo[3.2.1]octan-3-ol; 2-dimethylanunomethy^K3-metho^ 3-{^-cMoto-5-methoxy-pheriyl)-2-dimethylaminomethyl-bicyclo[3.2.1]oc 3>^^blGTO-S-m,e^xy-5keayiy2^ 2HJimethylaminometbyl-3-(5-methoxy-2-metiiyl-phenyl)-bi(^clo[3.2J]octan-3^ 2-dimethylaminometbyl-3-(3-metho^ 2-dimethylaininometbyl-3K3-hydroxy-phetiyl)-bicyclo[3.2J]octan-3-ol; 2-dimethylaminometbyl-3-(2-fluoro-5-hydroxy-phenyl>bicycio[3^.1]octan-3-ol; 2-dimethylaminomethyi-3-(3-fluoro-5-iiybicyclo[32.1]octan-3-ol; 2~dimethylaminometbyl"3-(3-hydroxy-5-trifluorome%l-phenyl)-bicyclo[3.2.1]octan 2-dimethylaminometbyI-3-(5-hydroxy-2-trifluorom^ 2-dmethylaminometbyl-3^3-hydroxy^-trifluoromethyl-phenyl)-bicyclo[3.2.1]octan-3-<)l; 2-dimethylaniinometbyl-3^4-fluoro-3-hy^ 2-dimethylaminomet!iyl-3^2-fluoro-3-bydroxy-phenyI>bicyclo[3.2.1]octanO 2-dimethylaminometfcyl-3-(3-hydroxy-5-methyl-^^ 3^2-cMoro-5-hydroxy-phenyl)-2Kiimet^ 3-(3-cMoro-5-hydroxy-phenyl)-2-dimethytaininbmetbyI-bicycTo[3.2.^ 2-toethylaminometliyl-3-(5-hyaVoxy-2-methy^ 2-dimethylaminome1l5yl-3-(3-hydroxy-4-methyl-pheayl)-bicyclo[3.2.l]octan-3-<)l; 3^3,4-difluoro-5-hydroxy-phenyl)-2-dimethylaminomethyl-bicycIo[3.2.1]octan-3-oI; 2-dimethylaminometiJyi-3-(2-fluoro-5-hydroxy-phenyl>bicyclo[3.2. Ijoctan -3-ol; 2,2-dimethyl-propionic acid 3-(2-dimethylaminomethyI-3-hydroxy-bicycte[3.2.1] benzoic acid 3-(2-diniethylaminomethyl-3-hydYox^^^ 2,2Kiimethyl-propionic ^id 3-(2^imethylam^ -phenyl ester, benzoic acid 3^2-dii^etnylai]^o™ethyl-3-nydioxy-bicyclo[3.2.1]oct-3-yl)-phenyI ester; 2,2-dimethyl-propionic acid 3-(2-dimethylaminomethyl-3-hydroxy-bicycIo[3.2. l]oct-3-yl) -5-fluoro-phenyl este£ or benzoic acid 3-(2^iim^ylamiiiomethyI-3-hydroxy-bicyclo[3 2.1 ]oct-3-yl)-5-fhioro-phenyl ester; or a salt thereof. The compound of claim 2 of the formula lb: 6. The compound of claim 5 wherein it is _ 3^4-diniemylamuiomethyl-bicycIo[3.2.1]oct-2-en-3-yI)-phenol; [3 -(3-methoxy-phenyl)-bicyclo[3.2.1 ]oct-3-en-2-ylmemyl]-dimethyl-aimne; [3K5-memoxy-2-trifluoromemoxy-phenyl)-bi(^ 3-(4-d^ethylaminomethyl-bicyclo[3.2. l]oct-2-en-3-yl)-4-trifluoromethoxy-phenoi; [3-(3-fluorp-5-memoxy-phenyl)-bicyclo[3.2.1]oct-3-en-2-ylmemyl]~dlmethyl-3 ^4^imethylaminomethyl-bicycIo[3.2 .lJ©ct-2-en-3-yl)-5-fluoro-pheno I; [3^2-fluoro-5-memoxy-phenyl)-bicyclo[3^.1]oct-3-en-2-ylmemyl]-d4memyl-amine; 3-(4^raemyianlinomemyl-bicycIo[3.2.1]oct-2-en-3-yI)-4-fiuoro-phenoI; [3-(3-methoxy-5-methyl-phenyl)-bicyclo[3.2.1 ]octO-en-2-yImemyl]-dimethyi-amme; 3-(4-dimemylaminomethyl-bicycIo[3.2.1]oct-2-en-3-yl)-5-methyl-phenol; 3^Moro-5^4-dimemylaniinomethyt-bicyclo[3.2.1]oct-2-en-3-yl)-phenol; [3^5-memoxy-2-methyI-phenyI)-bicyclo[3.2J3ort-3^n-2-yImemyl]-dUmemyl-amine; 3-(4-dimemylarmnomemyl-bicycIo[3^.1]oct-2-en-3-yl)^-methyl-phenol; 4-chloro-3-(4-dimethyIaminomethyl-bicyclo[3.2.i]oct-2-en-3-yl)-phenol; 2,2-dimethyI-propionic acid 3^4-dimethylaminomethyl-bicyclo[3.2.1]oct- 2-en-3-yl)-phenyI ester; benzoic acid 3^4-drniemylaminomethyl-bicyclo[3.2.1]oct-2-en-3-yl)-phenyl ester, 2,2-dimethyl-propionicacid 3-(4-dimethylaminomethyl-bicycIo[3.2.1 ]oct-2-en-3-yl) -5-fluoro-phenyl ester, isobutyric acid 3^4Klimemylaminomethyl-bicycIo[3.2.1]oct-2-en-3-yl)-5-fluoro-phenyl ester, 2,2-dimethyI-propionic acid 3-(4-dime&ykmMomethyi-bicyclo[3.2.1 ]oct-2-en-3-yl) -4-fluoro-phenyl ester, or isobutyric acid 3-(4-diniethylaminomethyl-bicyclo[3.2.I]oct-2-eli-3"-yl)-4-fluora-phenyl ester; or a salt thereof. 7. The compound of claim 2 wherein it is of the formula Ic: 8. The compound ofclaim 7 wherein it is: 3-(2-dimethylaminbmethyI -bicyclo[3.2.1]oct-3-yI)-phenol; [3-(3-methoxy-phenyiybicyclo[3:2J]oct-2-ytaemyl]Klimemyi-anune;, 3-(2^memylaminomethyl-bicyclo[3.2.1]oct-3-yl)-5-fluoro-phcnol; [3r(3-fluoro-5-methoxy-phenyl)-bicyclo[3.2.1 ]oct-2-ylmethyl]-dimethyl-amine; 3-(2-dimemylaminomethyl-bicyclo[3.2.1]oct-3-yl)-4-fluoro-phenol; [3-(2-fluoro-5-methoxy-phenyl)-bicyclo[3.2.1 ]oct-2-ylmethyl3-dimemyl-amine; 3-(2^imethylaininomethyl-bicyclo[3.2.1]oct-3-yI)-5-methyUphenol; [3^3-memoxy-5-methyl-phenyl)-bicyclo[3.2.1]oct-2-ylmethyl]-a^memyl^tnine; 2,2-dimethyl-propionic acid 3^2-dimethylaminomethyl-bicyclo[3.2.1]oct -3-yl)-phenyl ester, benzoic acid 3^2siimemylarninomethyt-bicyclo[3.2.1]oct-3-yl)-phenyt ester; 2^^imethy]-prppionic acid 3^2-dimethy]arju^omethyl-bicycIof3.2.1Joct-3-yi)-5-rluoro-phenyl ester; isobutyric acid 3-(2-dimemylainiiu)methyl-bicyclo[3.2.1]oct-3-yI)-5-fluoro-phenyl ester; 2,2^imethyl-propiom^ acid 3-(2-o^ethylammomethyl^ ester, or isobutyric acid 3^2-a%nethylarninomethyl-bicycIo[3.2.1]oct-3-yl)-4-fluoro-phenyl ester, or a salt thereof. The compound of claim 2 wherein it is of the formula Id: 10. The compound of claim 9 wherein it is ■a 3-dimethylaminomethyl-2-(3-hydraxy-phenyl)-bicycIo[4.1.0]heptan-2-ol; 3^limemylaminomethyl-2-(3-niethoxy-phenyl)-bicycio[4.1.0]heptan-2-ol; 3-dimethylaminomethyI-2-(3-fluoro-5-methoxy-phenyl)-bicyclo[4.1.0]heptan-2-ol; 3-dimethylarninomethyl-2-(5-methoxy-2-methyl-phenyl)-bicyclo[4.1.0]heptan-2^1; 3-dimethylaminome&yl-2-(3-methoxy-phenyl)-5,5-dimethyI-bicyclo[4.1.OJheptan-2-ol; 3-p^ethylarnmomemyl-2^3-hyaYoxy-phenyl)-5,5Klim 3-dimethylammomethyl-2-(3^fluoro-5-hydro«y~phenyI)-bicyclo[4.1.0] heptah-2-ol; 3^iimethylaininomethyl-2-(2-fluoro-5-hydroxy-pheiiyl)-bicyclo[4.1.03heptan-2^1; 3-dimeinylarranomethyl-2^3-hycu^xy-5-methyl-phenyl)-bicyclo[4;1.0]heptan-2-ol; 2,2-dimethyl-propionicacid3-(3Klunethylaniinomethyl-2-hydroxy-bicyclo[4.1.0]h^ 5-fhioro-phenyl ester, or 2^^imemyl-pn>pionic acid 3-(3^iimethyiajjim^ -4-fluoTo-phenyl ester, or a salt thereof. 11. The compound of claim 2 wherein it is of the formula Ie: 12. The compound of claim 11 wherein it is (lR,2MS,5S>2,6,6-trimethyl^((metoyl(phra (1 Sl2S,4R,5R)-2,6)6-trimethyl^(methyl(phenethyl)amino)methyl)bicyclo[3.1.1 ]heptan-3-one; (lR,2R,3S,4S,5S>3-(3-hydroxyphenyl>216,6-trmiemyM^(memyl(phenethyl)amm yclo[3.1; l]heptan-3-ol; (lR^R3S,4S,5S)-3-(3-methoxyphenyl)-2,6,6-trim^ yclo[3.1.1]heptan-3-ol; XlS£S^M^R)-3K3-hydroxyphenyi>2A6-ti^ yclo[3.1.1]heptan-3-ol; (lS,2S3R,4R,5R)-3-(3-methoxyphenyL>2,6,6~trimemyM^(methyl(phene%l)arnino)methyl)bi yclo[3.1.1 ]heptan-3-ol; or asalt thereof. 13. The compound of claim 2 wherein it is of the formula If: 14. The compound of claim 13 wherein it is 5^(dimethylamino)methyl)^-(3-hydroxyphenyl)octahydro-lH-inden-4-ol, or a salt thereof. 15. The compound of claim 2 wherein it is (+)-(lS,2R3R,5R)-2^(dimeraylarn^ (0-(lR^S3S,5S)-2-((a^memylarnmo)memyl)-3^3-hydroxyphenyl)bicyclo[3.2^ (S>3-((lS^R,3R,5R)-2^(dime%lamino)methyl)-3-hydroxybicyclo[3.2.1Joctan-3-yl)phenyl 2-phenylpropanoate hydrochloride; (S)-3<(lR,2S3S,5S)-2-((dimethylammo)methyI)-3-hydroxybicyclo[3.2.1]octan-3-yl)phenyl 2-phenyIpropanoate hydrochloride; 3-(4-dimethylaminomethyl-bicycld[3.2.1]oct-2-en-3-yl)-phenol; 3-((lS,5R)-2-((dimethylamino)methyl)bicyclo[3.2.I]oct-2-en-3-yl)phenol; and salts thereof. 16. A compound of claim 2 wherein it is of the formula Ig: 17. The compound of claim 16 where it is 5^1imemylammome^yI-6-{2-fluoro-5-hydroxy-phenyl)-spiro[2.5]octan -6-ol, or a salt thereof. 18. A pharmaceutical formulation comprising a compound of any of claims 1 through 17 and one or more pharmaceutically acceptable carriers. 19. The pharmaceutical formulation of claim 18 wherein it further comprises at least one additional active ingredient 20. The pharmaceutical formulation of claim 18 wherein it is a human pharmaceutical formulation, 21. The pharmaceutical formulation of claim 18 wherein it is veterinary pharmaceutical formulation. 22. A method of controlling pain in a mammal in need thereof comprising administering an effective amount of a compound of any of claims 1 through 17 to said mammal. 23. The method of claim 22 wherein at least one other active ingredient is administered to said mammal. 24. The method of claim 22 wherein said mammal is a human. 25. The method of claim 22 wherein said mammal is a companion animal. 26. The method of claim 25 wherein said companion animal is a dog or cat. 27. A compound or salt according any one of claims 1-17 for use in therapy. 28. A compound or salt according to anyone of claims 1-17 for use in controlling pain.